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Abstract 
Background: 
 Streptococcus pneumoniae can asymptomatically colonize the nasopharynx and cause a various 
range of illnesses. Pneumococcal conjugate vaccines (PCVs) are at present used in different 
countries. The aim of the study is to determine the effect of different vaccination policies 
PCV7/13 to that PCV10 on the carriage rates and comparing the impact of different vaccination 
policies in East Jerusalem and West Bank region. 
Methods: 
Five cross-sectional surveillances of S. pneumoniae were carried out in East Jerusalem and    
Palestinian authority (PA), where two Palestinian populations with different vaccination policies 
were screened, with an annual average of 348 and 616 children., respectively, were performed 
during 2009-2016. Nasopharyngeal swabs and data were collected from children less than 5 
years old visiting primary care physicians who visited any of three private pediatric clinics in 
Bethlehem, Nablus, and Ramallah in PA. In East-Jerusalem (EJ), PCV7 was implemented in 
2009 and replaced by PCV13 in late 2010, while in Palestine (PA), PCV10 was implemented in 
2011. 
 Swabs were streaked and incubated overnight at 35°C in 5% CO₂  enriched air to detect the   
presence of S. pneumoniae. Presumed colonies of S. pneumoniae were identified by morphologi-
cal characteristics, such as   hemolysis and optochin susceptibility. S. pneumoniae serogroup 
was determined by the latex agglutination test and S. pneumoniae serotype was determined and 
confirmed using PCR and gel-electrophoresis.    
 Results:  
A total of 4686 children were screened in EJ (n=1615) and PA (n=3070), the overall rate of S. 
pneumoniae carriage did not change significantly during the 5 first years of the study, in either 
population. The pediatric subjects from EJ were determined to carry S. pneumoniae during the 5 
years study, 2009, 2010, 2011, 2014, and 2016 as 28.9%, 29.3%, 26.9%, 30.7% and 16.9%,    
respectively. In addition 35.9%, 33.6%, 28.8%, 28.6% and 32.9% of the pediatric subjects from 
PA were shown to carry S. pneumoniae in 2009-2016, respectively. By year 2016, S. pneumoni-
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ae carriage was reduced significantly in EJ from ~29% on average to ~17%, following seven 
years application of PCV7/13. In PA, where follow-up included only 5 years after PCV10 appli-
cation, S. pneumoniae carriage remained ~30%. Interestingly, VT7 strains gradually decreased 
following PCV implementation. Following vaccine implementation, during the study period, 
there was a significant decrease in carriage of S .pneumoniae in the EJ between 2009 and 2016 
(P=0.001). No significant variation was seen in the overall carriage of S. pneumoniae between 
2009 to 2016 in PA (P=0.065). PCV10 was introduced to PA late in 2011, but S. pneumoniae 
carriage was approximately (160/566) 28% in2011, prior to vaccine introduction, and (216/656), 
32.9% in 2016, five years following vaccine implementation. 
In PA region, PA VT13-10 strains declined from 18.87% in 2011 to 9.78% in 2014, but re-
emerged to 18.06% in 2016. 
In both EJ and PA, a significant increase of non-VT isolates was observed between 2009 and 
2016 following vaccine implementation (P<0.0001 in both regions). Between 2009 and 2016, in 
EJ and PA, there was a decrease in PNSSP prevalence following vaccine implementation 
(p=0.2251 and p=0.1864, respectively).  
S. pneumoniae carriage among the parents was relatively rare, with 3.3% of parents detected as 
nasopharyngeal carriers in both regions throughout the five study years. 
Conclusions: Following PCV implementation, a decrease in the prevalence of VT strains was 
observed in EJ, and PA.  
Keywords: Streptococcus pneumoniae, pneumococcal conjugate vaccine, vaccine-type strain, 
non-vaccine type strains, 7-valent PCV (PCV7), 
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مقارنة التأثيرات المبكرة لسياسات التطعيم ضد الالتهاب الرئوي عمى النقل البمعومي لدى 
 السكان الفمسطينيين.
 اعداد:محمود احمد محمد رملاوي
 اشراف:د.كفاية عزمي
 :الممخص
 وتسبب مجموعةالبمعوم الأنفي بدون أعراض  السيطرة عمى لمكورات العقدية الرئويةا بامكان: خمفية الدراسة
في بمدان مختمفة. تيدف  )sVCP( تستخدم لقاحات المكورات الرئويةحاليا ض حيث متنوعة من الأمرا
 الاصابةعمى معدلات  01VCP وكذلك 31/7VCP الدراسة إلى تحديد تأثير سياسات التطعيم المختمفة
 ومقارنة تأثير سياسات التطعيم المختمفة في القدس الشرقية والضفة الغربية.
خلال الضفة الغربية و للالتياب الرئوي في القدس الشرقية دراسات مسحيو  :تم إجراء خمسة بحثمنهجية ال
من السكان الفمسطينيين مع سياسات التطعيم المختمفة ، بمتوسط  فحص قسمين ، حيث تم6102-9002
قل من أطفال توبيانات جمع مسحات البمعوم الأنفي  حيث تم .، عمى التواليطفلا 616و  843سنوي
 بالمناطق التالية وجودهالم سنة يزورون أطباء الرعاية الأولية من عيادات طب الأطفال 5.5أعمارىم عن 
، 9002في عام  ةفي القدس الشرقي 7VCP تنفيذب الاقرار  تم .بيت لحم ونابمس ورام الله في الضفة الغربية
 .1102في عام  01VCPنفيذ بينما في الضفة الغربية تم ت ، 0102اواخر عام   31VCP وحل محمو 
درجة مئوية من اليواء المخصب من ثاني أكسيد  53عند  ووضعيا في حاضنو تحمل  مسحاتال زراعةتم 
لمكشف عن وجود المكورات الرئوية. تم التعرف عمى المستعمرات المفترضة للالتياب طوال الميل الكربون 
. )ytilibitpecsus nihcotpoحساسية الاوبتشين(ا و الرئوي بالخصائص المورفولوجية ، مثل انحلال الدم ألف
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وتم تحديد المصل  المكورات الرئوية noitanitulgga xetal تم تحديد المكورات الرئوية عن طريق اختبار 
 .)siserohportcele-leg (واليلام الكيربائي RCPوتأكيدىا باستخدام 
) 0703=  ددع) والضفة الغربية (5161= ددعطفًلا في القدس الشرقية ( 6864مجموعو  تم فحصالنتائج:
ولم يتغير المعدل الإجمالي لمنقل العقدية الرئوية بشكل ممحوظ خلال السنوات الخمس الأولى من الدراسة ، 
المكورات الرئوية خلال  الذين يحممونالقدس الشرقية  فيالأطفال أي من السكان. تم تحديد اصابات  في
٪ ،  3.92٪ ،  9.82بنسبة  )6102، و  4102،  1102،  0102،  9002(دراسة السنوات الخمس  
٪ 8.82 ،٪ 6.33 ،٪ 9.53٪ ، عمى التوالي. بالإضافة إلى ذلك تبين أن  9.61٪ و  7.03٪ ،  9.62
٪ من الأطفال المصابين بالضفة الغربية يحممون التياب رئوي عمى التوالي. بحمول عام 9.23٪ و 6.82 ،
 تقريًبا، ٪71 إلى٪ في المتوسط 92الرئوية بشكل كبير في القدس الشرقية من  ، انخفض معدل نقل 6102
سنوات فقط من  5تشمل المتابعة بعد  الضفة الغربية فياما لمدة سبع سنوات.  31/7VCP تطبيق بعد
 )نوع المقاح سلالات ان٪. ومن المثير للاىتمام ، 03 المكورات الرئوية ما يقارب ، بقيت 01VCP تطبيق
 .)VCP(انخفضت تدريجيا بعد تنفيذ المقاح TV(7
بين عامي الرئوية في القدس الشرقية  البكتيريا في نقل ممحوظ ة ، كان ىناك انخفاضخلال فترة الدراس
 6102و  9002بين عامي  في النقل الكمي للالتياب الرئوي . لم يلاحظ أي اختلاف كبير6102و  9002
ولكن نقل الرئوية كان  ، 1102أواخر عام  فيالضفة الغربية إلى  01VCP. تم إدخال في الضفة الغربية
 6102٪ في عام  9.23) 612/656قبل إدخال المقاح ، و (  1102٪ في عام  82) 061/665حوالي (
أيًضا من  01-31TV في منطقة الضفة الغربية ، انخفضت سلالات مقاح، بعد خمس سنوات من تنفيذ ال
في  .6102٪ في عام 60.81، ولكن عادت إلى  4102٪ في عام 87.9إلى  1102٪ في عام 78.81
 IV
 
بين عامي  TVN سلالات غير نوع المقاح، لوحظت زيادة كبيرة في كل من القدس الشرقية والضفة الغربية
في القدس الشرقية ، 6102و 9002بين عامي  . في كمتا المنطقتين بعد تنفيذ المقاح 6102و 9002
مكورات الرئوية المقاومة ال ىناك انخفاض غير ميم من الناحية الإحصائية في انتشار كانوالضفة الغربية.
٪ من 3.3، حيث تم اكتشاف الالتياب الرئوي بين الوالدين نادًرا نسبًيا كان نقل. بعد تنفيذ المقاح نلمبنسمي
 .لخمسالآباء عمى أنيم حاملات البمعوم الأنفي في كمتا المنطقتين خلال سنوات الدراسة ا
القدس  في من نوع المقاح ، لوحظ انخفاض في انتشار سلالاتلقاح المكورات الرئوية : بعد تنفيذالاستنتاجات
 .الشرقية، الضفة الغربية
لقاح المكورات ، )eainomuenp succocotpertS( المكورات العقدية الرئوية الكممات المفتاحية:
سلالات من النوع ،   )TV(، سلالة من نوع المقاح))VCP eniccav etagujnoc laccocomuenpالرئوية
 . )TVN(غير المقاح
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Chapter One 
Background 
Pneumococcal infection caused by Streptococcus pneumoniae, cause high rates of morbidity and 
mortality. The main cause of deaths preventable by vaccination in children under age five 
worldwide (Brugger, Hathaway, and Mühlemann 2009). The World Health Organization (WHO) 
estimates that more than one million children die of pneumococcal disease in developing coun-
tries every year (WHO 2007). Community acquired pneumonia accounts for many of the severe 
diplococcus disease burden worldwide, although the danger of severe morbidity and death is 
highest for invasive pneumococcal disease (IPD) like bacteremia pneumonia, meningitis and   
sepsis(O‘Brien et al. 2009). The presence of S .pneumoniae in the nasopharynx of healthy    chil-
dren is indicative of the strains circulating and causing infections in the community, and has    
often been reported as being a precursor to waves of invasive disease and a major factor in the 
spread of infection (Cardozo et al. 2007; Van Kerschaver et al. 2004) 
Based on the structure of the capsular polysaccharides was split S. pneumoniae to more than 90 
distinct serotypes, which are considered to be the major virulence factors (Sjostrom et al. 2007). 
Only some of the serotypes cause disease and, of those that do, some have a greater capacity to 
invade and cause bacteremia. Others are more frequently associated with respiratory tract disease 
without a bacteremia, while still others remain limited to the nasopharynx, bacteria lacking a 
polysaccharide capsule rarely cause invasive disease (Melin et al. 2010). 
Prevention of infections caused by S. pneumoniae and their spread in young children is such an 
important goal of effective vaccination that new vaccines have been developed to achieve this. In 
2007, the WHO recommended that pneumococcal conjugate vaccine 7 (PCV7), which contains 
the polysaccharides of the serotypes 4, 6B, 9V, 14, 18C, 19F and 23F, be used in national      
immunization programs (NIP) (WHO 2007). Two more PCVs were recently introduced: PCV10, 
which contains the polysaccharides of the serotypes 1, 5, and 7F in addition to the serotypes of 
PCV7, and PCV13, which contains the polysaccharides of the serotypes 3, 6A, and 19A in addi-
tion to the serotypes of PCV10 (Thomas et al. 2007). PCVs of higher valence provide   broader 
serotype coverage (Harboe et al. 2008; Kaltoft et al. 2008). The use of PCVs in young children 
2 
 
creates herd immunity by reducing transmission and, thus, circulation of the bacterial serotypes 
opposed by the vaccine, leading to a decrease in invasive pneumococcal disease (IPD) in the 
population (Aristegui et al. 2007). 
Treatment of pneumococcal infections is becoming more difficult owing to the emergence of an-
tibiotic resistant pneumococci. Studies on serotype distribution and their antibiotic sensitivities 
are necessary for planning rational national strategies for preventing and treating IPD (Tsai et al. 
2006). Surveillance of pneumococcal diseases according to bacterial serotypes is essential, to 
learn about the current serotype distribution and to observe the efficacy of PCVs by following 
the dynamics of bacterial serotypes in the population, following the introduction of vaccination. 
Several studies have reported regional and temporal changes in the distribution of bacterial   
serotypes after the application of PCVs (Feikin and Klugman 2002). 
Kattan and colleagues (Kattan et al. 2011) described the distribution of invasive S. pneumoni-
ae from two Palestinian hospitals where bacteria of serotypes 6, 14, 1, and 9V predominated. 
The serotypes within serogroup 6 were not determined, however, it is important to identify the 
serotypes within serogroups such as serogroup 6 as serotype 6B polysaccharide is in PCV7 while 
serotypes 6A and 6C are not. 
Following an introductory trial of the PCV7 vaccine in a pilot study in the Hebron, Bethlehem, 
Jericho and Tubas districts in September 2010, this study was done to determine the rate of     
nasopharyngeal pneumococcal infection in healthy children, identify the serotypes of the        
circulating strains of S. pneumoniae and determine their antibiotic susceptibilities. 
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1.1Problem statement  
S. pneumoniae is an important cause of primary septicemia in children in the developing world. 
All disease states can lead to migration of S. pneumoniae from the site of infection into the 
bloodstream, resulting in pneumococcal sepsis. 
 
1.2 Study justification 
There are at least 40 serogroups of S. pneumoniae which are potentially pathogenic and possibly 
all are, but only a relatively small number of these groups accounts for the majority of IPD in 
children. There are geographic and age-related differences in the incidence of S. pneumoniae 
serotypes, and certain S. pneumoniae serotypes are recovered from IPD more frequently than 
others and have higher disease prevalence. 
 
1.3 Study hypotheses 
1) There are specific definable pathogen, host and population dependent factors that induce the 
evolution and spread of AR pathogens, and can explain the different Antibiotic Resistance (AR)      
patterns observed in our region.       
2) Advocating judicious antibiotic practices result in reduction of antibiotic use by the popula-
tion. 
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1.4 Study Goal 
To show the effects of the pneumococcal conjugate vaccine on pneumococcal carriage among 
children and to compare the effects of the different PCV vaccination policies among Palestinians 
living in Jerusalem and the West Bank. 
 
 
1.5 Study objectives 
1. To report the effect of PCV13 and PCV10 which has been introduced gradually in Palestine 
by identifying the serotypes. 
2. To determine the role of vaccination policies in effecting AR pattern 
3. To determine the role of antibiotic use patterns in inducing AR and its spread in the communi-
ty. 
4. To identify the non vaccine type (nVT) strains 
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Chapter two:  
Literature review 
 
2.1 S. pneumoniae carriage and burden of disease 
Pneumonia is a common disease affecting children, especially in developing countries 
(Izadnegahdar et al. 2013). Streptococcus pneumoniae (S. pneumoniae) is the predominant bacte-
ria responsible for community acquired pneumonia (T.J. and M.B. 2005). 
S. pneumonia was known in 1881 by Sternberg(Sternberg and Flaumenhajtt 1993). The pneumo-
coccus could be a lancet formed gram positive diplococcus characterized by a surrounding poly-
saccharide capsule. Since it's alpha hemolytic, bile soluble and optochin sensitive, it can be 
known by standard microbiological tests, using morphological characteristics and biochemical 
tests (Desai et al. 2015). Based on the structure of the capsule, the pneumococci will be sub-
classified and more than 90 antigenically totally different serotypes (subtypes) have been record-
ed. Some non encapsulated variants of pneumococci exist, additionally called  non typeable 
pneumococci (van der Poll and Opal 2009). 
Streptococcus pneumoniae is a common human pathogen that causes high morbidity and       
mortality rates(Nasereddin et al. 2013). Epidemiological studies show that colonization of the 
neonatal respiratory tract with S. pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis         
significantly increases the risk of asthma in the first 5 years of life as well as Haemophilus      
influenzae, or Moraxella catarrhalis (Rhedin 2017). Yearly, pneumococcal disease results in               
≈ 600,000 deaths among children <5 years of age globally, with the majority occurring in 
Africa(Kassebaum et al. 2014). 
In 2000, out of a total 10,600,000 deaths worldwidly, pneumococcal disease caused 826,000 
deaths of children under the age of 5 years(O‘Brien et al. 2009). Out of 90 Streptococcus             
pneumoniae serotypes that have been identified(Calix et al. 2012), approximately 20 are         
responsible for the majority of invasive pneumococcal disease (IPD) (Rudan et al. 2013). 
6 
 
S. pneumoniae infection is a common cause of acute otitis media, as well as more life threatening 
illnesses such as pneumonia, meningitis, and septicemia (O‘Brien et al. 2009).       Individuals 
who is Immunodeficient or those with anatomical asplenia, particularly sickle cell disease, are 
more susceptible to developing invasive pneumococcal disease (IPD) than the general popula-
tion. Other risk factors include low socioeconomic status, upper respiratory and influenza infec-
tions, smoking, old age, and heart, liver and lung comorbidities (Butler and Schuchat 1999). 
Nasopharyngeal S. pneumoniae carriage is the source for horizontal transmission of the pathogen 
between individuals and is the endogenous source for infection. Colonization of S. pneumoniae 
is generally asymptomatic and is a part of the nasopharyngeal flora established in individuals, 
but may sometimes develop into disease (Brugger, Hathaway, and Mühlemann 2009). S. pneu-
moniae is commonly carried by children under 5 years of age (Brugger, Hathaway, and 
Mühlemann 2009). 
Risk factors correlated with previous antibiotic use,  presence of young siblings high carriage 
rates include, age,  and day care center attendance (Regev‐ Yochay, Keller, et al. 2004). In this 
study, S. pneumoniae was carried by only 4% of the adults, compared with 53% of children in 
the same community. Young age, day care center attendance, having young siblings, and no          
antibiotic use during the month before screening were associated with the high carriage rate 
among children, whereas the only risk factor associated with carriage among adults was the  
presence of a respiratory infection on the screening day. The trans oral nasopharyngeal and   
oropharyngeal swabs increase carriage detection in the adult population. The Frequency of     
carriage in children can be under the influence of environmental factors such as seasonal factors 
and crowded or closed settings (Rioux et al. 2011). Such as in the winter season, pneumococcal      
carriage and disease trends be likely to be higher and is in part due to the winter viral respiratory 
infection (Zhou et al. 2012). Nasopharyngeal colonization by S. pneumoniae typically persists 
for several months after the first exposure, but with age, acquisition of new serotypes results in 
shorter durations of carriage. Rarely, a colonization event results in invasion to other sites, such 
as the ears, sinuses, lungs or blood. Children under two years of age and adults older than 65 
years of age are the most susceptible populations for pneumococcal disease. Because of that, the 
risk to human health posed by S. pneumoniae underscores the necessity and urgency of studying 
the bacteria. 
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2.2 The Pneumococcal Capsule 
Pneumococci have many virulence factors, including capsular polysaccharides, pneumolysin, 
pneumococcal surface protein A (PspA), pneumococcal surface protein C (PspC), and         
pneumococcal surface adhesin A (PsaA). Capsular polysaccharides are considered to be the most 
important virulence factor as they surround pneumococci and protected them from phagocytes. 
Currently, 94 capsular serotypes, including the recently reported serotypes 6C, 6D, 11E, and 
20A/20B, have been reported (J. Y. Song, Nahm, and Moseley 2013) and at least 23 serotypes 
commonly cause invasive pneumococcal disease (IPD)(J. Y. Song, Nahm, and Moseley 2013). 
Streptococcus pneumoniae can asymptomatically colonize the nasopharynx and cause a various 
rang of illnesses.                               
This clinical spectrum from Colonization to invasive pneumococcal disease (IPD) appears to   
depend on the pneumococcal capsular serotype rather than the genetic background. Serotypes are 
serologically distinguishable strains belonging to the pneumococcal bacteria based on the     
structure of the capsular polysaccharides (J. Y. Song, Nahm, and Moseley 2013).  
 
Types of S. pneumoniae that are antigenically associated are labeled with the same numerical 
value and assigned different letters, i.e. same serogroup, but different serotype (van Dam, Fleer, 
and Snippe 1990). These specific serotypes have been targeted for vaccine coverage(van Dam, 
Fleer, and Snippe 1990). 
 
Pneumococcal capsules play the most important role in pathogenesis, and they have a great    
implication in vaccine development. Of note, serotype distributions of pneumococcal capsules 
vary geographically and temporally in terms of nasopharyngeal carriage, pathogenicity and    
clinical presentation (Hausdorff, Siber, and Paradiso 2001). The capsular polysaccharide            
structure plays a role in evading the host‘s immune system, including defense mechanisms such 
as phagocytosis, and persisting in carriage  Serotype that produce heavily encapsulated           
polysaccharides avoid being phagocytosed, continue colonization within the host and persist in 
prevalence (Brandes et al. 2009). 
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The determination of pneumococcal serotypes is key to assess the effects of PCVs, including de-
creases in PCV serotypes and potential non PCV serotype replacement following the use of the 
vaccine over time. With PCVs being increasingly introduced into the routine infant  immuniza-
tion programs of several low and middle income countries serotype specific pneumococcal sur-
veillance is key to assess the impact of the vaccine in diverse settings. 
 
2.3 Pneumococcal Vaccines 
Pneumococcal Polysaccharide Vaccine 23 (PPSV23) 
In 1983, a 23-valent PPV (PPV23) was approved and developed a capsular polysaccharide    
vaccine targeting the 23 common serotypes (PPSV23) including serotypes: 1, 2, 3, 4, 5, 6B, 7F, 
8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 20, 22F, 23F, and 33F (Örtqvist, Hedlund, 
and Kalin 2005), which intensifying serotype coverage to more than 85% of the organisms caus-
ing IPD at the time (Rastogi et al. 2011). Covalent coupling of the polysaccharide to a protein 
carrier effectively converts the T-cell-independent Type 2 polysaccharide into a T-cell-dependent 
antigen; carrier proteins include a non toxic mutant of diphtheria toxin (CRM197), as well as 
other proteins such as protein D of non typeable Haemophilus influenza (Black et al. 2000). 
PPSV23 elicits a T cell independent immune response which makes it ineffective in children 
younger than 2 years of age (Bridy-Pappas et al. 2005),which make it not licensed for the them, 
while it was good for immune competent adult patients in the United States. 
2.4 Pneumococcal Conjugate Vaccine (PCV) 
The poor immunogenicity of T-cell-independent PPSV23 in infants led to development of the 
pneumococcal conjugate vaccine (PCV). 
The introduction of pneumococcal conjugate vaccines (PCVs) into routine infant immunization 
programs worldwide has led to significant decreases in overall incidence of invasive pneumo-
coccal disease (IPD), both in children and in adults (Esposito and Principi 2015).Unlikely, 
PPSV23, pneumococcal conjugate vaccines offer mucosal immunity, additionally acting upon 
cavum carriage acquisition, and thereby providing an indirect impact additionally to an on the 
spot community impact.  
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In 2000, the first 7-valent PCV (PCV7) was licensed in the United States (US) in and introduced 
to Korea in 2003. This PCV included capsular polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 
19F, and 23F, representing approximately 80%-90% of IPD in children (Abu Seir et al. 2018). 
While PCV7 was introduced to the United States in 2000, the vaccine was available in Israel for 
individual purchase since 2007 and implemented through the National Immunization Plan (NIP) 
in 2009. However, the protective coverage of PCV7 was reduced, due to the serotype shifts    
resulting from vaccine pressure, and PCV7 did not include serotypes 1, 3, and 5, which are 
common in Europe, Asia, and Africa (Hausdorff, Siber, and Paradiso 2001).Therefore, a 13-
valent PCV (PCV13), which included serotypes 1, 3, 5, 6A, 7F, and 19A, was introduced for 
children in 2010 and later licensed for adults in 2012. 
Since 2010, two improved pneumococcal conjugate vaccines, PCV13 and PCV10 became   
available to many countries. In Portugal, although available only in the private market, the      
introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) in 2001 led to significant 
changes in the serotypes responsible for pediatric IPD (pIPD) (Aguiar et al. 2008). Among the 
most relevant changes was the rise of non PCV7 serotypes 1, 7F and 19A as major causes of 
pIPD. During this period uptake peaked at 75% around 2008. In mid 2009, PCV10 became 
available, including PCV7 serotypes and additionally serotypes 1, 5 and 7F. Soon after this, in 
early 2010, PCV13 was introduced in Portugal, further including serotypes 3, 6A and 19A, and 
became the leading vaccine used in Portugal. 
 PCV13 was licensed and introduced in 2010 in the United States and in Israel a few months later 
(October 2010). In addition to the seven S. pneumoniae serotypes already found in PCV7, 
PCV13 includes six additional highly invasive serotypes: 1, 3, 5, 6A, 7F, and 19A. The serotypes 
found in PCV13 target 80%-90% of the pneumococcal capsular serotypes that were responsible 
for pneumococcal disease in the USA in the pre PCV era (Daniels, Rogers, and Shelton 2016). 
PCV10 contains serotypes found in PCV7 with three additional serotypes: 1, 5, and 7F. In a    
custom randomized trial conducted in Brazil, the effectiveness of PCV10 was found to be 83.8% 
against vaccinated serotypes and 77.9% against vaccine related serotypes(de Moraes et al. 2014). 
While they suggested that cross-reactivity for 19A high (82%) and low to 6A (15%), most stud-
ies, as well as a meta-analysis, report the opposite (Isturiz et al. 2017). 
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PCV 10 were used in Bangladesh, Belgium, Brazil, Chile, Colombia, Fiji, Finland, Georgia,   
Iceland, Nepal, Netherlands, Paraguay, and Peru.  And PCV13 was used in Argentina, Australia, 
Canada, Costa Rica, Czech Republic, Denmark, France, Greece, Guatemala, Hungary, Ireland, 
Israel, Italy, Japan, Mexico, New Zealand, Nicaragua, Norway, Poland, Portugal, Russian     
Federation, Switzerland, Turkey, United Kingdom, United States, and Uruguay. Both PCV10 
and PCV 13 were used in Austria, Estonia, Germany, Republic of Korea, Philippines, Slovakia, 
Slovenia, Sweden, and the Palestinian Authority.  
PCV10 and PCV13 are the vaccines currently used in countries employing a pneumococcal   
conjugate vaccine. PCV10 consists of carrier protein from conserved lipoproteins of non type-
able Haemophilus influenzae, while in PCV7 and PCV13 the carrier protein of a non-toxic mu-
tant is the diphtheria toxin (Earnshaw et al. 2012). In an 8 years case control study conducted in 
Canada, protection against any IPD was 72% for PCV10 and 66% for PCV13 (where PCV     
effectiveness is calculated as one minus the odds ratio). Both vaccines were highly effective in 
conferring protection against serotypes targeted by each respective vaccine. Moreover, both   
vaccines displayed high levels of cross protection against IPD caused by serotype 19A, 71% by 
PCV10 and 74% by PCV13 (Cané, Hamelin, and Isturiz 2015). A study conducted in Finland in 
2009-2010 showed that PCV10 confers herd immunity and displays cross protection against 
serotypes 19A and 6A in children less than 1.5 years of age (Jokinen et al. 2015). 
In vaccine eligible children, significant reduction in PCV10 related IPD including 6A and 
19A,suggesting that PCV10 may provide cross protection against vaccine related serotypes and 
consist with the  study that done in Brazil  that reported the significant effectiveness of PCV10 
against serotype 19A (de Moraes et al. 2014). 
PCV10 is cheaper; compared to PCV13, PCV13 covers 3 additional serotypes (3, 19A and 6A), 
which are a significant cause of IPD and has been suggested to provide higher protection against 
acute otitis media and IPD that may be caused by Haemophilus influenzae (Daana et al. 2015; 
Wu et al. 2015). In contrast, serotype 19A IPD prevalence was found to increase following 
PCV10 implementation in Columbia (Isturiz et al. 2017). Additionally, PCV13 was found to be 
more cost effective when compared to PCV10 by  protecting against more IPD cases and deaths, 
even though PCV10 is cheaper (Ordóñez and Orozco 2015). A meta-analysis using published 
data from countries were PCV7, PCV10, and PCV13 were introduced, suggested that PCV7 and 
PCV10 do not appear to display herd protection against serotype 19A, while PCV13 was shown 
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to reduce IPD caused by serotype 19A and displayed herd protection against serotype 19A 
(Isturiz et al. 2017).A meta-analysis of 63 studies conducted between January 2006 through   
January 2014 concluded that both PCV10 and PCV13 are beneficial alternatives to PCV7, and 
the most optimal choice of vaccine for any country is dependent on several factors that vary by 
location, such as serotype replacement, serotype cross-protection, herd effects, cost-
effectiveness, and the epidemiological distribution of serotypes present in the population (Wu et 
al. 2015).In 2017, 141 countries are known to have introduced or planned to introduce the pneu-
mococcal conjugate vaccine. PCV13 is in use in 101 countries, PCV10 is in use in 33    coun-
tries, and 8 countries are using both PCV10 and PCV13 (Satzke et al. 2019). 
 
2.5Cinical Presentations   
Different clinical presentations of pneumococcal diseases are known due to different  pneumo-
coccal serotypes. Globally, serotypes 3, 6A, 6B, 9V, 14, 19A, 19F, and 23F were reported to 
cause acute otitis media (AOM) in young children (J. Y. Song, Nahm, and Moseley 2013). Sero-
type 19A pneumococcal acute otitis media increased predominantly after the introduction of 
PCV7 (Mahjoub-messai et al. 2009). Particularly, serotypes 3, 11A, and non typeable (NT) 
pneumococci are associated with acute conjunctivitis (Shouval et al. 2006).Concerning IPD, 
serotypes 1, 5, and 7F usually affect healthy young adults with a low mortality rate, while sero-
types with low or intermediate invasive potential are more possible to affect the elderly with un-
derlying comorbidities (Shouval et al. 2006)compared the incidence and serotype distribution of 
IPD among children less than 18 yr of age between the early (2001-2006) and late (2007- 2010) 
periods of the PCV7 era in the US. Overall IPD incidence rate was 7.5 cases per 100,000 popula-
tion and was not statistically different from the observed incidence in 2001 to 2006 (P > 0.05). 
The     proportion of bacteremia pneumonia among all IPD cases was almost 3-fold greater in 
2009 to 2010 (P < 0.01). PCV7 serotypes represented for 7%, whereas the 13-
valent pneumococcal conjugate vaccine serotypes accounted for 77% of all cases between 2007 
and 2009. IPD due to serotypes 19A and 7F increased, and 19A and 7F were isolated in 41% and 
20% of all IPD cases in the same period, respectively. However, serotypes causing IPD have 
changed pointedly in the last decade.  
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According to a meta-analysis (J. Y. Song, Nahm, and Moseley 2013), pneumococcal serotype 14 
was the most prevalent etiologic agent of pneumococcal CAP, followed by serotypes 1 and 5, in 
Latin America and the Caribbean, which included the post-PCV7 periods, serotype 1 was      
predominant, followed by serotypes 19A and 3. The prevalence of serotype 14 was decreased to 
around 5%. 
Serotypes 1, 3, 7F, 14, and 19A are known to be associated with empyema complications after 
pneumococcal infection (Krallis 2006). Also, According to surveillance in Ugandan children 
aged less than five years, the most common serotype was 6A/6B (40%), followed by 22A, 23F, 
14, and 19A (Kisakye et al. 2009). Previously, serotypes 1, 3, and 5 were rarely reported in cases 
of meningitis (Kisakye et al. 2009).   
Continual surveillance is important to determine the impact of 13 valent pneumococcal conjugate 
vaccine, as well as track potential changes in disease incidence and character due to non            
13 valent pneumococcal conjugate vaccine serotype. 
2.6 Serotype Replacement 
Following widespread introduction of PCV7, the pneumococcal population has changed. Non 
vaccine serotypes (NVTs) have increased among asymptomatic carriers in a process called  
―serotype replacement(Biology 1997), and to a lesser extent, NVTs have also increased as    
causes of invasive disease. While the reported magnitude of this increase in disease among 
NVTs has been relatively modest in most countries, such changes have the potential to reduce 
the overall public health benefit of the vaccine. Consequentially, non-vaccine type strains take 
over the vacant niche and are the major colonizers in that niche, a phenomenon known as sero-
type replacement (Huang et al. 2005). 
 
Preceding to PCV7 implementation, seven serotypes caused the majority of invasive disease. 
Following PCV7 introduction, there was an increase in the non-VT-7 serotypes in the nasophar-
ynx of individuals. Yet, the risk for IPD declined. PCV7 strains were nearly eliminated and only 
a minimal increase in non-VT strains was observed (Feikin et al. 2013). 
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Following nasopharyngeal serotype replacement, a lag was observed in the increase of IPD 
caused by non-VT serotypes, and varies in different populations and different geographical      
locations(Weinberger, Malley, and Lipsitch 2011). The six serotypes included in PCV13 (and 
not PCV7) were chosen, due to their known high virulence, it was therefore not surprising that 
they were among the most common emerging non-VT IPD causing serotypes replacing VT7 
serotypes. Particularly, serotype 19A emerged dramatically in the United States and raised    
concern(Singleton et al. 2007). While serotype replacement is a universal phenomenon, which 
serotype among the non-VT serotypes emerge and replace the decreasing VT serotypes differs in 
different geographic locations. For example, a study in the United States reported that several 
year following PCV7 implementation, serotypes 19A, 6A, 15B/C, 35B, and 11A were observed 
to emerge and serotype 19A was particularly a high IPD causing serotype(Huang et al. 2005). 
While a study in Portugal reported that serotypes 1, 3, 7F, and 19A are the most common causing 
IPD serotypes following PCV7 implementation (Aguiar et al. 2008). Following PCV7             
introduction, a universal increase in non-VT 13-7 serotypes was observed with some variation, 
but these serotypes were generally invasive. Following the introduction of PCV13, non-VT13 
serotypes may emerge in the nasopharynx of individuals and follow the same trend that was   
observed after the introduction of PCV7(Weinberger, Malley, and Lipsitch 2011). There is 
strong evidence that colonization with NVTs increases in vaccinated populations. Randomized 
trials involve vaccination as the cause of these increases, and observational sign is reliable with 
theoretical estimates that both larger reductions in VT carriage and larger increases in NVT   car-
riage must occur after mass vaccination. 
 
2.7Antibiotic Resistance 
In contrast to the capsular serotype, the genotype is more closely associated with antibiotic     
resistance. The capacity of S. pneumoniae to undergo horizontal gene transfer leads to its genetic 
diversity and aids the organism adapt to environmental changes, including antibiotic pressure. 
Theoretically, the genotype should primarily correlate with antibiotic resistance. 
In a study done by Song et al., 2013 (J. Y. Song, Nahm, and Moseley 2013), he presented that 
Isolates belonging to serotypes 3 and 18C that were 100% sensitive to penicillin were             
significantly less competent than isolates belonging to serotypes 6B, 14, 19F, 9V, and 23F, 
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which were frequently resistant to penicillin. Intriguingly, the capsule (cps) locus of S.        
pneumoniae is flanked by the pbp2x and pbp1a genes, which code for penicillin-binding proteins 
(PBPs) (Thompson and Lipsitch 2004). PBPs are enzymes involved in cell wall synthesis and are 
targets for β-lactam antibiotics. Under the natural selection imposed by host immunity and       
antibiotics, the recombination events would involve PBP genes, as well as the cps operon, and 
would change both the serotype and the resistance profile of the strain. 
Globally, the prevalence of antibiotic resistant S. pneumoniae has increased and related to the 
spread of pediatric pneumococcal serotypes (6A, 6B, 9V, 14, 15A, 19F, 19A, and 23F). After the 
introduction of PCV7, the prevalence of PCV7 serotypes and serotype 6A were decreased and 
subsequently replaced by non-PCV7 serotypes, including serotype 19A. Although           
Spain23F-ST81 and Spain6B-ST90 were well-established multidrug-resistant clones in the 1980s 
and 1990s, their prevalence decreased after the introduction of PCV7 (Ardanuy et al. 2009). 
Serotype 19A is the most prominent serotype worldwide, CC320/271 strains with serotype 19A 
are multidrug resistant and prevalent worldwide, particularly in North America and many Asian 
countries(J. Y. Song, Nahm, and Moseley 2013)both clinically important and multidrug-resistant 
(non-susceptible to ≥ 3 antibiotic classes) in the era of PCV7. More than 30% of serotype 19A 
isolates were multidrug resistant (Hulten et al. 2013).Among isolates with serotype 19A, 86.0% 
and 79.8% showed erythromycin resistance and MDR, respectively(J. Song et al. 2004). 
With dual macrolide resistance mechanisms (ermB and mefA), they showed resistance to eryth-
romycin, tetracycline, clindamycin, cefuroxime, and trimethoprim/ sulfamethoxazole (J. Song et 
al. 2004). Erythromycin resistance was highly correlated with azithromycin and clarithromycin 
resistance(Shin et al. 2011). Although the resistance rate for penicillin is quite low (minimum 
inhibitory concentration [MIC] ≥ 8 μg/mL, < 5%). Several clones of multidrug-resistant serotype 
6C pneumococci emerged in the US and Europe, and a multidrug resistant 6D clone (ST282) has 
been identified in Korea (117- 119, 138, 139).The relations between the pneumococcal serotype 
and genotype were addressed with regard to antibiotic resistance.  
Knowledge of the serotype distribution is important for conjugate vaccine usage, but the sero 
epidemiological data is insufficient in many countries. A nationwide sero surveillance system is 
vital to start. 
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2.8Culturing and molecular techniques 
Culture remains the gold standard for the identification of the organism while the Quellung     
reaction remains the gold standard for serotype determination from isolates. Nonetheless, culture, 
is highly specific but has low sensitivity, requires long incubation periods and is not    commonly 
available in many low-income countries (Slotved et al. 2004). In addition, antibiotic therapy pri-
or to specimen collection or suboptimal culturing conditions may reduce the yield of      cultures 
(Pai, Gertz, and Beall 2006). Polymerase chain reaction (PCR)-based methods targeting pneu-
mococcal specific genes, such as lytA, have resulted in improved and timely diagnosis of pneu-
mococcal diseases (Yu et al. 2005). The method involves streamlined DNA template     prepara-
tion and agarose gel electrophoresis to analyze the amplification products. Capsular types identi-
fied by the PCR method invariably produced results concordant with the conventional   serotyp-
ing technique. Even when the method presented does not fully type an isolate, the PCR data can 
guide the experimenter when using immunological serotyping. Multiplex PCR for the analysis of 
pneumococci provides an accurate, expeditious, and cost-effective way of reducing the number 
of strains that have to be serotyped by conventional immunological techniques (Satzke et al. 
2014).Such methods can be easily implemented where molecular diagnostic capacity exists and 
could become an alternative diagnostic tool in settings where culture capacity is lacking or 
suboptimal. Nonetheless, the use of molecular diagnostic techniques for the evaluation of the 
impact of PCVs against IPD has been documented (Earnshaw et al. 2012). 
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Chapter Three:  
Methodology 
 
3.1 Study design, sample source and study population 
The study is a repeated cross sectional surveillance of S. pneumonia carriage that was performed 
in 2016, to assess and isolate pneumococci from nasopharyngeal samples collected from Pales-
tinian children who are living under two different policies for vaccination in East         Jerusalem 
(EJ) and West Bank (PA), and then compare it with the previous 4 cross sectional   surveys that 
done during the months May through July of 2009, 2010, 2011 and  2014 from the  two Palestin-
ian populations. 
The results that we got here are compared to two previous studies done by Daana et al., 2015 and 
Abu Seir et al., 2018 to show the effects of PCVs (7, 10, 13) on streptococcal pneumonia naso-
pharyngeal carriage in studied population.  
S. Pneumoniae carriage among Palestinian children (<5 years) is performed among two        
proximate Palestinian populations, living under two distinct health authorities, with different 
PCV vaccination policies (PCV7, PCV10 and PCV13). Areas of the Palestinian Authority has its 
own health ministry and began implementing PCV10 in late 2011, while East Jerusalem is    
governed by the Israeli Ministry of Health, and therefore implemented PCV7 in 2009 and 
PCV13 in 2010. This study provided a unique opportunity to study over-all and indirect effects 
of PCV7, PCV10 and PCV13 vaccination, in two closely related Palestinian populations       
governed by two distinct health authorities.  
In this way, the study is designed to evaluate the effect of two different pneumococcal conjugate 
vaccine policies (PCV7/13 vs. PCV10) by comparing EJ and PA.It was thus possible to conduct 
an observational study that simulated some what a theoretical desired clinical trial measuring 
vaccine effectiveness, where PCV13 was introduced to one population, but not yet to the other. 
Here, the effects of PCVs on Streptococcus pneumoniae carriage, distribution of serotypes and 
antibiotic resistance patterns are reported. Children under 5.5 years of age residing in the West 
Bank under the PA who visited any three, private pediatric clinics in Bethlehem, Nablus, and 
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Ramallah were recruited by physicians conditional upon parents informed and signed consent. 
Samples were then transported to Al-Quds University Laboratory. 
3.2 Data Collection 
Each study participant filled a questionnaire by parents who were questioned to obtain medical 
information and demographics of the parent and child including, age, gender, day care            
attendance the life style and daily habits, environmental exposure, health and family history and 
socioeconomic information such as parent‘s profession, smoking habits, breastfeeding history, 
and type of pets owned. Medical information included chronic history of illnesses or recurrent 
illnesses, antibiotic use during the recent period, immunizations, hospitalizations during the past 
6 months, and current medical status. 
3.3 S. pneumoniae Screening and Laboratory 
 
A nasopharyngeal swab, using rayon-tipped aluminum shaft swab placed in Amies transport me-
dia (Copan innovation, Brescia, Italy) was collected. Samples were transported within 24 hours. 
Swabs were streaked on tryptic soy agar plates supplemented with Sheep-blood and 
5micrograms/ml gentamycin (Hy-labs) and were incubated overnight at 35°C in 5% CO₂         
enriched air to detect the presence of S. pneumoniae. Presumed colonies of S. pneumoniae were 
further tested and identified by morphological characteristics, such as   hemolysis and optochin 
susceptibility. Other types of streptococcus are not susceptible to optochin. Once confirmed as S. 
pneumoniae, the sample was grown on tryptic soy broth agar (TSBA) blood plates (Hy-labs) 
overnight under the same conditions. S. pneumoniae samples were swabbed from TSBA and  
inserted in brain heart infusion (BHI) with 30% glycerol and was frozen at -80°C preserve for 
further characterization. 
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Figure 3A: Isolates from Early Years of Collection 
During the study (2016), we characterized all of the S. pneumoniae samples that were collected 
from EJ, and PA. 
 
3.4 Antibiotic Susceptibility Testing 
Swabs were streaked on tryptic soy agar plates supplemented with Sheep-blood and 5 ug/ml gen-
tamicin and were incubated overnight at 35◦C in 5% CO2-enriched air. S. pneumoniae were 
identified using morphological characteristics, alpha hemolysis and optochin susceptibility. Epi-
solemeter test (E-test) strips for penicillin and ceftriaxone susceptibility were used following 
Clinical and    Laboratory Standards Institute (CLSI) guidelines. Strains with MIC ≤ 0.06 g/ml 
were defined as penicillin-susceptible S. pneumoniae (PSSP), strains with MIC > 0.06  g/ml as 
penicillin non susceptible S. Pneumonia (PNSSP) and strains with MIC ≥ 2  _g/ml as penicillin 
resistant S. pneumoniae (PRSP). Antibiotic susceptibility to erythromycin, clindamycin, trime-
thoprim/sulfamethoxazole, ofloxacin and vancomycin was determined by disk-diffusion. Multi-
drug resistance (MDR) was defined as at least non susceptibility to penicillin and erythromycin 
resistance. 
Defining multidrug resistance as non susceptibility at minimum to penicillin with a MIC greater 
than 0.06 mg/L and erythromycin with a MIC greater than 0.5 mg/L. Essentially growth          
inhibition of antibiotic susceptibilities via disk diffusion was determined according to the       
Clinical and Laboratory Standards Institute (CLSI) guidelines as can be seen in Table 3.1. 
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Disk/ E-test strip S (mm) I (mm) R (mm) MIC (S) MIC (I) MIC (R) 
Vancomycin ≥17 -- -- ≤1 -- -- 
Trim/Sulfamethoxazole ≥19 16-18 ≤15 ≤0.5 1-2 ≥4 
Levofloxacin ≥17 14-16 ≤13 ≤2 4 ≥8 
Ofloxacin ≥16 13-15 ≤12 ≤2 4 ≥8 
Erythromycin ≥21 16-20 ≤15 ≤1 3 ≥4 
Clindamycin ≥19 16-18 ≤15 ≤0.25 -- ≥1 
Penicillin    ≤0.06 0.12-1 ≥2 
Ceftriaxone    ≤1 2 ≥4 
 
Table 3.1: Standard sensitivities to antibiotics according to the CLSI 
 
3.5 Serotype Determination 
The serogroup of the isolate was determined by latex agglutination test, bacteria colonies were 
grown overnight on TSBA blood plates 35°C in 5% CO₂ . Serogroup and serotype were deter-
mined by the latex agglutination test and the Quellung reaction (StatenSerum Institute, Copenha-
gen, Denmark).  
 The kit consists of 14 pneumococcal polyclonal pool antisera, (pools P to T and A to I). 10 μl of 
cell line was applied to disposable latex agglutination cards mixed with a pneumococcal sample 
retrieved from the TSBA blood plate with 1.50 μl of one pool antiserum. The solution was stirred 
and the card was rocked for 5-10 s. Agglutination signified a positive reaction, and was read by 
the naked eye. Agglutination occurs if the antiserum is homologous to the capsule of the  pneu-
mococcal culture. Specific combinations of antisera yield certain serogroups within 20 s. Pneu-
mococcal samples were classified as omni negative when it does not react with the antisera. This 
method is sensitive and less expensive since it may be used as a screening tool to quickly identi-
fy the serotype, which subsequently can be confirmed by Quellung reaction. 
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Please see Table 3.2 for combinations of antisera pools used and the serotypes resulting from 
these combinations. 
Pool  P  Q  R  S  T     
A  1 18A/B/C/F 4 5 2   
B  19A/B/C/F 6A/B/C 3 8     
C  7A/B/C/F       20 24/A/B/F, 31, 40 
D      9A/L/N/V   11A/B/C/D/F 16A/F, 36, 37 
E      12A/B/F 10A/B/C/F 33A/B/C/D/F 21, 39 
F        17A/F 22A/F 27, 32A/F, 41A/F 
G            29, 34, 35A/B/C/F, 42, 
47A/F 
H  14  23A/B/F   15A/B/C/F   13, 28 
I            25A/F, 38, 43, 44, 45, 
46, 48 
 
 
Table 3.2: Distribution of the chessboard system of pneumococcal strains according to their 
serotypes using Pneumotest-Latex 
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3.6 Freezing of S. Pneumoniae Isolates 
A pure fresh isolates of S. pneumoniae were streaked on blood agar to be inoculated, then, in 
bacterial preserver vials containing 25% glycerol at -80 °C until needed. 
The freezing solution was prepared as the following: 37.8 gram of brain heart infusion broth 
(BHI) were weighed and suspended in a graduated cylinder with ddH2O till 750mL. The solu-
tion was mixed well to become homogenous and 250ml of pure glycerol were added. Then, the 
mixture was mixed well and autoclaved. After autoclaving, each 1 ml of the prepared      freezing 
mixture was aliquoted in a screw capped sterile eppendorf tubes and freezed at -30 °C to be used 
for the collected isolates. 
 
3.7 DNA Extraction and Quantification 
Genomic DNA was extracted from overnight fresh cultures either by boiling method as            
described below  and/or using the DNA extraction Kit ―Nucleospin, Macherey-Nagel, Germany‖ 
(NucleoSpin® 2017). 
For the extraction by boiling, a loopful suspension of overnight grown cultures on blood agar 
plates was prepared in 1.5 ml microcentrifuge tube containing a prepared lysis solution of 95 ul 
of  sterile nuclease free distilled water, one microliter of lysostaphin (1 mg/mL), one microliter 
of  lysosyme (1mg/mL),one microliter of 1M Tris and 2 ul  0.5M EDTA. The suspension was 
first incubated at room temperature for 5 min. then, incubated at 37 °C  for 30 min and then   
heated in dry bath incubation at 95 °C  for 10 min. the suspension was centrifuge at 10,000 rpm 
for 5 min; the supernatant was collected in a new clean collection microcentrifuge tube and used 
as DNA template. 
Regarding the extraction by the Nucleospin Kit, it was done according to the manufacturer‘s   
instructions with some modifications Briefly,2-3 pure colonies were suspended in 180 ul T1 
buffer and 25 ul proteinase K solution. Samples were completely covered with this lysis solution 
and colonies were lysed by vigorous vortex yielding to a turbid mixture. T1 buffer and proteinase 
K mixture are stable for 10-15 min before addition of samples because proteinase K tends to self-
digest in T1 buffer without substrate. Thus, it was pre-mixed directly before use only.   However, 
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it is important to add proteinase K to digest proteins and remove contamination from preparation 
of nucleic acid. Then, the mixture was incubated in a shaking incubator overnight at 56 °C until 
complete lysis is obtained. After lysis 200 ul of B3 buffer were added to each sample, vortexed 
vigorously and incubated at 70 °C for 15 min. Then, after incubation, samples were vortexed 
vigorously and adjusted for the DNA binding step. Then, 210 ul absolute ethanol (96-100%) 
were added to each sample, vortexed vigorously, and loaded to the NucleoSpin® Tissue column 
silica membrane with the collection tube, provided by the Kit. Then, samples were     centrifuged 
for 1 min at 11,000 x g and first wash was done by adding 500 ul BW buffer and centrifuged for 
1 min at 11,000 x g. After centrifugation, the flow through solution was discarded and columns 
were placed into new collection tubes. Second wash was done by adding 600 ul B5 buffer to the 
column and centrifugation for 1 min at 11,000 x g. Then, the flow through solution was discard-
ed and the silica membrane columns were allowed to dry by centrifuging the columns with the 
collection tubes for 1 min at 11,000 x g. Residual ethanol is removed during this step. 
The final step, the elution step was modified to yield to high pure and high concentration DNA. 
Half volume of elution buffer (50 ul) was added to the column and incubated for 10 min at room 
temperature before centrifugation. The elution buffer was pre-heated at 60°C to dissolve the   
pellet well. After centrifugation, the second half of the elution buffer (50 ul) was added to the 
column and incubated, also for 10 min at room temperature, then centrifuged again. By this, 
about 85-100% of bound nucleic acid is eluted in the standard elution volume and at a high   
concentration. 
The extracted DNA by the two methods was stored at -30 °C for the molecular analysis. 
The concentration of DNA were measured by a Nanodrop ND-1000 UV-Vis spectrophotometer 
(Thermo Fisher Scientific Inc, Waltham MA, USA). The instrument was adjust using 1 ul       
distilled water as a blank for the boiling method and the Kit elution buffer as a blank for ncleo-
spin Kit extraction method. The protein/DNA ratio (260/280 nm) was measured to estimate the 
purity of DNA samples. Whereas, samples with purity less than 1.2 were not used and               
re-extracted again. 
The boiling method was faster and simpler, but the DNA extraction by Kit had shown higher   
purity and better stability of the DNA upon storage for further use. 
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The DNA concentration used for molecular typing of all samples ranged between 10-200 ng/ul 
However, the volume of template DNA was increased for samples with low concentration and 
the highly concentrated DNA were diluted with nuclease free distilled water for better yield and 
purity. Figure3.1 (A) shows a summarized table taken randomly selected extracted samples that 
were used as template DNA for the Serotyping. Figure3.1 shows a representative graph for     
extracted DNA sample measured by the Nanodrop. 
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Figure 3.1: A: a table taken as snapshot from the (Nanodrop 1000 spectrophotometer) for some repre-
sentative randomly selected extracted samples that were used as template DNA for the serotyping. B: a 
graph of representative extracted DNA sample as examined on the Nanodrop 1000 spectrophotmeter. 
 
 
A 
B 
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3.8 Molecular typing of serotype-specific genes encoding the capsule locus in 
S. pneumonia: 
Following latex agglutination and determination of the serogroup, S. pneumoniae serotype was 
determined and confirmed through PCR and identified through gel electrophoresis. Based on the 
results of serotyping as serogroups that were positive by agglutination, the specific serotype of 
that serogroup were determined by PCR Multiplex PCR based approach for deducing serotypes 
done as described by (Feikin et al. 2013). The serotypes included (1, 2, 3, 4, 5, 8, 13,14, 20, 21, 
31, 34, 37, 38, 39, 40, 44, 46, 6A, 6B, 7A, 7B, 7C, 7F, 9A, 9N, 9L, 9V,10A, 10F, 11A, 11D, 
11F, 12A, 12B, 12F, 15A, 15B, 15C, 15F, 16A, 16F, 17F,18A, 18B, 18C, 18F, 19A, 19F, 19C, 
22F, 22A, 23A, 23B, 23F, 25F, 28A, 24F, 33F,33A, 35B, 35F, 35A, 35C, and 47F). Table 3.3 
lists the primers used in the single or multiplex PCR for the serotyping. 
The PCR mix contained 10 μl ddH2O, 12.5 μl Ready Mix (PCR Master Mix by ABgene), 1.25 
μl of the forward primer and 1.25 μl of the reverse primer per sample. or, PCR-ready                 
product™  from syntezza (Pilishvili et al. 2010).In the case where two pairs of primers were 
used, then ddH2O was adjusted according to 7.5 μl to maintain a total of 25 μl PCR mix per PCR 
test tube.   
The reaction conditions consist of 35 cycles at 95°C for 30 s, 54°C or 62°C for 1 min and 30s 
and 72°C for 1 min, followed by 10 min at 72°C. The reaction differed for serogroup 6 in that the 
reaction conditions consist of 35 cycles at 94°C for 30 s, 62°C for 1 min and 72°C for 1 min per 
kilobase, followed by 10 min at 72°C. PCR reactions were carried as described by (Feikin et al. 
2013). In all amplification reactions, negative controls (mix without DNA) and positive controls 
(from pervious of PCR‘s in this study). 
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3.9 Agarose gel electrophoresis: 
Agarose gel was cast and run in 2.0% agarose gels (FMC BioProducts, Rockland, ME,USA) run 
at 120 V in 1 X Tris–acetate–EDTA buffer,  containing ethidium bromide (0.5g/mL) for          
visualization by UV light using a gel documentation system (the Bio-Imaging systems Mini  
Lumitransilluminator). The 100 bp or 1Kb molecular weight standard ladders (Thermo Scientific 
GeneRuler) was used as molecular weight standards for each gel. 
 
Table 3.3: List of primers sequences used for pneumococcal serotype deduction by PCR and  
target amplicons. 
Serotype Primer Sequence (5’-3’) Base 
Pair 
Length 
anneal-
ing Tem 
 Multiplex   Re-
action 
1 1-f: CTC TAT AGA ATG GAG TAT ATA AAC TAT GGT TA 
1-r: CCA AAG AAA ATA CTA ACA TTA TCA CAA TAT TGG C 
280 49 Reaction 1 
9N/L 9N/L-f: GAA CTG AAT AAG TCA GAT TTA ATC AGC 
9N/L-r: ACC AAG ATC TGA CGG GCT AAT CAA T 
516 49 Reaction 1 
7F 7F-f: CCT ACG GGA GGA TAT AAA ATT ATT TTT GAG 
7F-r: CAA ATA CAC CAC TAT AGG CTG TTG AGA CTA AC 
826 49 Reaction 1 
10F/C 10F/C-f: GGA GTT TAT CGG TAG TGC TCA TTT TAG CA 
10F/C-r: CTA ACA AAT TCG CAA CAC GAG GCA ACA 
248 55 Reaction 2 
6C 6C-f: CAT TTT AGT GAA GTT GGC GGT GGA GTT 
6C-r: AGC TTC GAA GCC CAT ACT CTT CAA TTA 
727 55 Reaction 2 
4 4-f: CTG TTA CTT GTT CTG GAC TCT CGA TAA TTG G 
4-r: GCC CAC TCC TGT TAA AAT CCT ACC CGC ATT G 
430 55 Reaction 2 
2 2-f: TAT CCC AGT TCA ATA TTT CTC CAC TAC ACC 
2-r: ACA CAA AAT ATA GGC AGA GAG AGA CTA CT 
290 53 Reaction 3 
7F/A 7F/A-f: TCC AAA CTA TTA CAG TGG GAA TTA CGG 599 53 Reaction 3 
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7F/A-r: ATA GGA ATT GAG ATT GCC AAA GCG AC 
9V/A 9V/A-f: GGG TTC AAA G TC AGA CAG TG A ATC TTA A 
9V/A-r: CCA TGA ATG A AA TCA ACA TT G TCA GTA GC 
816 53 Reaction 3 
10A 10A-f: GGT GTA GAT TTA CCA TTA GTG TCG GCA GAC 
10A-r: GAA TTT CTT CTT TAA GAT TCG GAT ATT TCT C 
628 51 Reaction 4 
21 21-f: CTA TGG TTA TTT CAA CTC AAT CGT CAC C 
21-r: GGC AAA CTC AGA CAT AGT ATA GCA TAG 
192 51 Reaction 4 
39 39-f: TCA TTG TAT TAA CCC TAT GCT TTA TTG GTG 
39-r: GAG TAT CTC CAT TGT ATT GAA ATC TAC CAA 
98 51 Reaction 4 
23A 23A-f: TAT TCT AGC AAG TGA CGA AGA TGC G 
23A-r: CCA ACA TGC TTA AAA ACG CTG CTT TAC 
722 54 Reaction 5 
23B 23B-f: CCA CAA TTA G CG CTA TAT TCA TTC AAT CG 
23B-r : GTC CAC GCT GAA TAA AAT GAA GCT CCG 
199 54 Reaction 5 
23F 23F-f: GTA ACA GTT GCT GTA GAG GGA ATT GGC TTT TC 
23F-r: CAC AAC ACC TAA CAC TCG ATG GCT ATA TGA TTC 
384 54 Reaction 5 
19A 19A-f: GAG AGA TTC ATA ATC TTG CAC TTA GCC A 
19A-r: CAT AAT AGC TAC AAA TGA CTC ATC GCC 
566 52 Reaction 6 
24 24-f: GCT CCC TGC TAT TGT AAT CTT TAA AGA G 
24-r: GTG TCT TTT ATT GAC TTT ATC ATA GGT CGG 
99 52 Reaction 6 
35A/C 35A/C-f: ATT ACG ACT CCT TAT GTG ACG CGC ATA 
35A/C-r: CCA ATC CCA AGA TAT ATG CAA CTA GGT T 
280 52 Reaction 6 
12F 12F-f: GCA ACA AAC GGC GTG AAA GTA GTT G 
12F-r: CAA GAT GAA TAT CAC TAC CAA TAA CAA AAC 
376 49 Reaction 7 
31 31-f: GGA AGT TTT CAA GGA TAT GAT AGT GGT GGT GC 
31-r: CCG AAT AAT ATA TTC AAT ATA TTC CTA CTC 
701 49 Reaction 7 
38/25A/F 38/25-f: CGT TCT TTT ATC TCA CTG TAT AGT ATC TTT ATG 
38-/25r: ATG TTT GAA TTA AAG CTA ACG TAA CAA TCC 
574 49 Reaction 7 
15A/F 15A/F-f: ATT AGT ACA GCT GCT GGA ATA TCT CTT C 
15A/15F-r: GAT CTA GTG AAC GTA CTA TTC CAA AC 
434 50 Reaction 8 
33F 33F-f: GAA GGC AAT CAA TGT GAT TGT GTC GCG 338 50 Reaction 8 
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33F-r: CTT CAA AAT GAA GAT TAT AGT ACC CTT CTA C 
35F/47F 35F/47F-f: GAA CAT AGT CGC TAT TGT ATT TTA TTT AAA GCA 
A 
35F/47F-r: GAC TAG GAG CAT TAT TCC TAG AGC GAG TAA 
ACC 
517 50 Reaction 8 
34 34-f: GCT TTT GTA AGA GGA GAT TAT TTT CAC CCA AC 
34-r: CAA TCC GAC TAA GTC TTC AGT AAA AAA CTT TAC 
408 52 Reaction 9 
35B 35B-f: GAT AAG TCT GTT GTG GAG ACT TAA AAA GAA TG 
35B-r: CTT TCC AGA TAA TTA CAG GTA TTC CTG AAG CAA G 
677 52 Reaction 9 
14 14-f: GAA ATG TTA CTT GGC GCA GGT GTC AGA ATT 
14-r: GCC AAT ACT TCT TAG TCT CTC AGA TGA AT 
189 52 Reaction 9 
11A/D 11A/D-f: GGA CAT GTT CAG GTG ATT TCC CAA TAT AGT G 
11A/D-r: GAT TAT GAG TGT AAT TTA TTC CAA CTT CTC CC 
463 53 Reaction 10 
3 3-f: ATG GTG TGA TTT CTC CTA GAT TGG AAA GTA G 
3-r: CTT CTC CAA TTG CTT ACC AAG TGC AAT AAC G 
371 53 Reaction 10 
13 13-f: TAC TAA GGT AAT CTC TGG AAA TCG AAA GG 
13-r: CTC ATG CAT TTT ATT AAC CG C TTT TTG TTC 
655 53 Reaction 10 
5 5-f: ATA CCT ACA CAA CTT CTG ATT ATG CCT TTG TG 
5-r: GCT CGA TAA ACA TAA TCA ATA TTT GAA AAA GTA TG 
362 49 Reaction 11 
6A/B/C 6A/B/C-f: AAT TTG TAT TTT ATT CAT GCC TAT ATC TGG 
6A/B/C-r: TTA GCG GAG ATA ATT TAA AAT GAT GAC TA 
250 49 Reaction 11 
9V 9V-f: CTT CGT TAG TTA AAA TTC TAA ATT TTT CTA AG 
9V-r: GTC CCA ATA CCA GTC CTT GCA ACA CAA G 
753 49 Reaction 11 
15B/C 15B/C-f: TTG GAA TTT TTT AAT TAG TGG CTT ACC TA 
15B/C-r: CAT CCG CTT ATT AAT TGA AGT AAT CTG AAC C 
496 49 Reaction 11 
6A/B 6A/B-f: AAT TTG TAT TTT ATT CAT GCC TAT ATC TGG 
6A/B-r: TTA GCG GAG ATA ATT TAA AAT GAT GAC TA 
250 49 Reaction 12 
18 18-f: CTT AAT AGC TCT CAT TAT TCT TTT TTT AAG CC 
18-r:  TTA TCT GTA AAC CAT ATC AGC ATC TGA AAC 
573 49 Reaction 12 
16F 16F-f: GAA TTT TTC AGG CGT GGG TGT TAA AAG 
16F-r: CAG CAT ATA GCA CCG CTA AGC AAA TA 
717 53 Reaction 13 
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6B 6B-f: CGA CGT AAC AAA GAA CTA GGT GCt GAA AC 
6B-r: AAG TAT ATA ACC ACG CTG TAA AAC TCT GAC 
220 53 Reaction 13 
18C 18C-f: GCA TCt GTA CAG TGT GCT AAT TGG ATT GAA G 
18C-r: CTT TAA CAT CTG ACT TTT TCT GTT CCC AAC 
354 53 Reaction 13 
7C/B 7C/B-f: CTA TCT CAG TCA TCT ATT GTT AAA GTT TAC GAC 
GGG A 
7C/B-r: GAA CAT AGA TGT TGA GAC ATC TTT TGT AAT TTC 
260 52 Reaction 14 
35F 35F-f: GAA CAT AGT CGC TAT TGT ATT TTA TTT AAA GCA A 
35F-r: GAC TAG GAG CAT TAT TCC TAG AGC GAG TAA ACC 
517 52 Reaction 14 
17F 17F-f: TTC GTG ATG ATA ATT CCA ATG ATC AAA CAA GAG 
17F-r: GAT GTA ACA AAT TTG TAG CGA CTA AGG TCT GC 
693 52 Reaction 14 
8 8-f: GAT GCC ATG AAT CAA GCA GTG GCT ATA AAT C 
8-r: ATC CTC GTG TAT AAT TTC AGG TAT GCC ACC 
294 55 Reaction 15 
22F 22F-f: GAG TAT AGC CAG ATT ATG GCA GTT TTA TTG TC 
22F-r: CTC CAG CAC TTG CGC TGG AAA CAA CAG ACA AC 
643 55 Reaction 15 
19F 19F-f: GTT AAG ATT GCT GAT CGA TTA ATT GAT ATC C 
19F-r: GTA ATA TGT CTT TAG GGC GTT TAT GGC GAT AG 
304 50 Reaction 16 
20 20-f: GAG CAA GAG TTT TTC ACC TGA CAG CGA GAA G 
20-r: CTA AAT TCC TGT AAT TTA GCT AAA ACT CTT ATC 
514 50 Reaction 16 
 
3.10 Ethical Considerations: 
The IRB approvals were giving by local Research Ethical Committee at Al-Quds University for 
this study. Written informed consent was given by a parent for each participating child before 
recruitment. Also a permission from the Palestinian Ministry of Health (MOH) was obtained to 
review the clinical reports of patients and to collect the demographic data of patients. 
3.11 Statistical Analysis: 
Each isolate was coded, and data were analyzed using the Statistical Package for Social Sciences 
(SPSS) version 20. Descriptive statistics for all samples were presented as frequencies and      
percentages. 
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Chapter Four 
Results 
4.1 Study Design and study Population: 
 Palestinian population under two health policies; East Jerusalem (EJ) vs Palestinian authority 
(PA), two closely related Palestinian populations governed by two distinct health authorities, in 
five repeated cross-sectional surveillances during 2009 and 2016. 
 
A total of 4,696 children under 5.5 years of age from both EJ and PA, joined the study during the 
years 2009, 2010, 2011, 2014, and 2016, with an annual average of 348 and 616 children,       
respectively. In EJ, children (n=1,740), full data were available for 1616, under Israeli Health 
policy who visited specific pediatric clinics were recruited. In the West Bank, children (n=3,080) 
under the Palestinian Authority who visited any of three, large private pediatric clinics in     
Bethlehem, Nablus, and Ramallah were recruited. Repeated cross-sectional surveillances were 
carried out in EJ and PA during summer season. The pediatric subjects from EJ were determined 
to carry S. pneumoniae during the 5 years study, 2009, 2010, 2011, 2014, and 2016 as 
(100/345,28.9%), (91/311, 29.3%),  (87/324,26.9%), (88/287,30.7%), and (59/348,16.9%),     
respectively. In addition, (223/620, 35.9%), (200/595, 33.6%), (160/566,28.8%),  
(184/643,28.6%), and (216/656,32.9%) of the pediatric subjects from PA were shown to carry S. 
pneumoniae, respectively. 
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Figure4.1: A map of Jerusalem (Al-Quds) and the West Bank showing the distribution of S. 
pneumoniae among cities in 2016 which are included in this study (Sampling area). 
 
71(25.6%) 
59(21.3%) 
78(28.2%) 
65(23.5%) 
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Full demographic data for each isolate including: the hospitalization period, age group, patient 
type, gender, place of residence and breastfed. 
Place of residence for all included patients was documented from questionnaire. The most      
frequent regions of the collected isolates were from Nablus (78, 28.2%) followed by the Bethle-
hem (71, 25.6%), Ramallah (65, 23.5%) and East Jerusalem (59, 21.3) Table 4.1 
Region 2016 Frequency (SP) Percent % 
East Jerusalem (EJ) 48 3.12 
Nablus (N) 67 3713 
Ramallah (R)  54 3214 
Bethlehem (B) 6. 3415 
Total 366 .1111 
 
Table 4.1: Number of Patients and their place of residence in this study. 
  As shown in figure 4.2A&B show, there was no significant change in the prevalence of car-
riage of pneumococci in any of the examined regions. The only significant change was   ob-
served in EJ in 2016, when pneumococcal carriage decreased significantly as compared to all 
previous years, and this is the most important limitation to change some stereotypes that not 
found in this region 
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Fiqure 4.2A: Total samples and % of SP carriage in EJ 
 
2009 2010 2011 2014 2016
TOTAL 345 311 324 287 349
SP 100 91 87 88 59
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Fiqure 4.2B: Total samples and % of SP carriage in PA 
 
A detailed description of the study population of the first four surveys (2009–2014) was         
previously reported(Abu Seir et al. 2018; Daana et al. 2015) Here, we present an additional   sur-
veillance that took place in 2016 in which 349 children from EJ and 656 children from PA were 
screened Figure 4.1. Population characteristics in this surveillance are slightly similar to those in 
the 4 initial surveillances, with aproportion of males (59.6% and 40% in PA and EJ), However, 
gender of 6(0.4%) of the samples were not found figure4.2. 
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Fiqure 4.3A: S.pneumoniae distribution according to gender in both EJ and PA. 
According to age, figure 4.3B shows the age distribution. Age was categorized to two age 
groups, as the following:  1; from 0-24 months, 2; more than 2 years. Approximately, 67.5% of 
the children between 0 and 24 months and almost 31.7% of the children more than 2 years.     
Accordingly, 73.1% (158/216) and 47.5% (28/59), of the children under age of 2 years old in PA 
and EJ respectively. Regarding breast fed, Nearly similar in both regions, where 94.9% and 
97.2% in EJ and PA respectively. About 36, 16.7% of children from PA were hospitalized, and 
only four 6.8%  children from EJ. 
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Fiqure 4.3B: S.pneumoniae distribution according to Age in both EJ and PA. 
4.2  Detection of S. pneumoniae by Optochin susceptibility and Serotypes. 
All of the S. pneumoniae samples were identified using morphological characteristics,              
alpha hemolysis and optochin susceptibility. E-test strips for penicillin and ceftriaxone             
susceptibility and the serogroup of the isolate is determined by latex agglutination test after that 
we confirmed the serotypes using PCR. Fiqure4.4 is a gel electrophoresis for detection of the 
23A/B/F serotype. 
67.5% 
31.7% 
0.8% 
Child Age 
1=Less than two
years
2=More than or
equal to two years
NK
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Fiqure 4.4: A representative agarose gel electrophoresis for the 23A/B/F serotypes detection    . 
M:100 bp DNA molecular weight marker. Band size 23A=722, 23B=199 and 23F=384 
 
4.3 Vaccination uptake history and during the study period 
The 7-valent PCV (PCV7) was available in private markets in EJ in 2009, but the vaccine was 
not implemented in the National Immunization Plan (NIP) during the first study year 2009. In 
2009, less than 3% of the children received PCV7and <2% in PA received at least one dose of 
PCV7. After PCV7 was added to the NIP in EJ in 2010, the percentage of children in EJ         
receiving at least one dose of the vaccine increased to 74.9% and at least two doses of the      
vaccine to 57.8%. In late 2011, PCV10 was officially given in PA, and 13.1% children were    
estimated to be vaccinated that year (Daana et al., 2015), while it was 15 (4.1%) in 2010.Prior to 
PCV10 implementation in PA, in 2010 only 4.1% of children under the age of 2 received at least 
one dose of PCV7 (Daana et al., 2015). This proportion increased to 85.5% in PA three years 
after implementing PCV10 in the vaccination program compared to 92% of children in EJ. 
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In 2016 study, (28/29) 96.6% and (148/158) 93.7% of the children who had SP, which were less 
than two years old, were immunized with one or two dose in EJ and PA respectively.  However, 
(30/30, 100%) and (52/58, 89.7%) were detected for children who were above two years old in 
both regions EJ and PA respectively. Interestingly, in 2016 study, 92.6% (200/216) and 98.3% 
(58/59) of children were vaccinated in both regions, PA and EJ., respectively. Table 4.2 
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Age of child Region 
Not vaccinated 
N(%) 
Vaccinated 
N(%) Total 
< 2 years 
old 
EJ . 37 38 
  213%  8515%  .1111%  
PA .1 .37 .47 
  512%  8216%  .1111%  
Total .. .65 .76 
  418%  831.%  .1111%  
> 2 years 
old 
EJ 1 21 21 
  111%  .1111%  .1111%  
PA 5 43 47 
  .112%  7816%  .1111%  
Total 5 73 77 
  517%  8213%  .1111%  
Total EJ . 47 48 
  .16%  8712%  .1111%  
PA .5 311 3.5 
  613%  8315%  .1111%  
Total .6 347 366 
  51.%  821.%  .1111%  
 
Table 4.2: Distribution of age groups of patients were that vaccinated from during study. 
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4.4S. pneumoniae Carriage 
Carriage was detected in 425/1616 (26.3%) children in EJ and 983/3080(31.9%) in PA during 
the five-year study period. Similarly to previous study (Daana et al. 2015) findings where the 
carriage was detected in 279 (28.5%) children in EJ and 583(32.9%) in PA during the three-year 
study period. 
Following vaccine implementation, during the study period, there was a significant decrease in 
carriage of S. pneumoniae in the EJ between 2009 and 2016 (p=0.001). 
 
 
Figure 4.5A. Distribution of VT isolates and non-VT (NVT) isolates of S. pneumoniae in     
children from EJ.Bars represent S. pneumoniae carriage as a distribution of VT7 isolates,     
VT7-10 isolates, VT13-7 isolates, and non-VT-13 isolates of all isolates in each year. 
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In the PA region, no significant variation was seen in the overall carriage of S. pneumonia  be-
tween 2009 to 2016 (p=0.065). PCV10 was introduced to PA late in 2011, but S. pneumonia car-
riage was approximately (160/566) 28% in2011, prior to vaccine introduction, and (216/656), 
32.9% in 2016, five years following vaccine implementation. Figure 4.5B. 
 
 
Figure 4.5B. Distribution of VT isolates and non-VT (NVT) isolates of S. pneumoniae in     
children from PA.Bars represent S. pneumoniae carriage as a distribution of VT7 isolates,    
VT7-10 isolates, VT13-7 isolates, and non-VT-13 isolates of all isolates in each year. 
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Figure4.6: In EJ and PA, the effect of the vaccination was seen in the distribution of                   
S. pneumoniae strains during the study period. 
 
4.5 Serotype Distribution 
Prior to the introduction of PCV7 in EJ and PCV10 in PA, all 13 serotypes present in the       
vaccine, vaccine-type (VT) strains, represented 60% of all S. pneumoniae isolates (see in ap-
pendex 6.1). Since the additional 3 serotypes belonging to PCV10: 1, 5, 7F were not detected in 
the study population between 2009 and 2016 just one case in 2009 in EJ and three cases in 
PA,one case in 2009, 2010 and 2011 in PA., respectively, VT7 and VT13-10 (VT13-10 isolates 
include serotypes 3, 6A, and 19A) SP strains were used to compare the effects of the two vac-
cines in EJ and PA. 
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Fiqure 4.7A:Serotype distribution of vaccine type (VT10-7) in EJ 
 
Fiqure 4.7B: Serotype distribution of vaccine type (VT10-7) in PA 
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In EJ, VT7 strains decreased significantly since the introduction of PCV7 and continued to     
decrease through 2016 (p<0.0001). VT7 strains in PA followed same trend as in EJ since the   
introduction of PCV10 in late 2011.  
In EJ, the prevalence of VT7 strains was 47.00% in 2009. Following PCV7 implementation, the 
prevalence declined to approximately 26.4% by 2010 and 24.00% by 2011. Following PCV13 
implementation, the prevalence of VT7 strains further decreased to 5.7% by 2014. However, in 
2016 an increase in the prevalence of VT7 strains was observed to reach (13.5%) figure 4.8B. 
 
 
Fiqure 4.8A: Serotype distribution of vaccine type (VT7) in EJ 
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Fiqure 4.8B: Serotype distribution of vaccine type (VT7) in PA 
In both EJ and PA there is an overall decrease in all VT7 strains between 2009 and 2016,     
(Figure 4.8A and 4.8B) primarily serotypes 19F, 14, 6B, and 23F.in EJ, by 2016 serotypes 6B 
and 19A were eliminated, serotype 19F re-emerged following elimination in 2014. Five years 
following PCV10 implementation, by 2016, the prevalence of serotype 19A and 6A increased 
significantly (p=0.0150 and p=0.0213, respectively) 
In PA region, PA VT13-10 strains declined as well from 18.87% in 2011 to 9.78% in 2014, but 
re-emerged to 18.06% in 2016. There was no observable effect of PCV10 implementation on the 
prevalence of VT13-10 isolates during the study period (p=0.9772).  If we assess the reduction in 
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VT10 strains 2 to 3 years following the introduction of either PCV7 or PCV10, i.e. in 2011 for 
EJ, and in 2014 for PA, a reduction of approximately 20% was seen. Moreover, in EJ and PA 
there was a statistically significant increase in non-vaccine type (non-VT or NVT) strains by 
2016 (both p<0.0001) Fiqure 4.9A&B. 
 
 
Fiqure 4.9A: VT13-10 strains in EJ decreased significantly (p=0.0327) from 2009 (14.00%) to 
2014 (6.9%), followed by decrease in 2016 (3.4%). 
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Fiqure 4.9B: PA VT13-10 strains declined as well from 18.87% in 2011 to 9.78% in 2014, but 
re-emerged to 18.06% in 2016. 
 
Following PCV10 implementation in PA, VT7 strains decreased significantly from 41.25% in 
2011 to 16.20% in 2016 (p<0.0001) Fiqure4.9. 
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Fiqure 4.10: VT7 in PA strains decreased significantly from 41.25% in 2011 to 16.20% in 2016 
(p<0.0001). 
Between 2009 and 2016, the prevalence of VT7 isolates and VT13-10 isolates decreased         
significantly (p<0.0001 and p=0.0327, respectively) in EJ (Figures 4.8A&4.9A). In PA, the 
prevalence of VT7 isolates decreased significantly during the study period (p<0.0001)(Fiqure 
4.8B), while there was no significant change in the prevalence of VT13-10 isolates (Figure 
4.9B). 
 In both EJ and PA, a significant increase of non-VT isolates was observed between 2009 and 
2016 following vaccine implementation (p<0.0001 in both regions).  
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Figure 4.11A: Serotype Distribution of non VT Serotypes in EJ in each year. 
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Figure 4.11B: Serotype Distribution of non VT Serotypes in PA in each year. 
 
NonVT13 serotypes gradually replaced VT13 serotypes; therefore, overall carriage of  S. pnemo-
nia did not change significantly in both regions. The proportion of non-VT13 strains increased 
from 38.0% of all isolates in pre-PCV surveillance in 2009, to 83% five years after the introduc-
tion of PCV13 in EJ (p<0.001). As for PA, the proportion of non-VT13 serotypes      increased 
from 39.4% in the pre-PCV period (2011) to 65.7% in 2016 (p<0.001). Table 4.3A&B presents 
the most common non-VT13 serotypes in both regions and their proportion among all isolates 
during the four surveillance periods, as well as p-values of the change pre to post-vaccine peri-
ods. By 2016, In both EJ and PA, the Five most common non-VT-13 serotypes are 
11A/D(63.45), 15B/C (62.8%) ,35B(38.44%) ,15A/F(36.7%) and 19B/C(20.03%). 
 
 
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
nVT-PA 
2010 2011 2014 2016
51 
 
nVT -EJ(total %) 2009 (%) 2010 (%) 2011 (%) 2014 (%) 2016 (%) 
19B/C 0.00 0.00 4.60 7.95 0.00 
25/38 0.00 3.30 1.15 6.82 0.00 
22F 0.00 0.00 0.00 3.41 0.00 
6C 0.00 4.40 3.45 2.27 0.00 
12 0.00 1.10 0.00 3.41 0.00 
10A/B 2.00 1.10 1.15 4.55 0.00 
33F 2.00 1.10 3.45 1.14 1.69 
35B 4.00 2.20 8.05 6.82 1.69 
17F 4.00 4.40 4.60 0.00 1.69 
10A 0.00 0.00 0.00 0.00 3.39 
23A 1.00 3.30 2.30 3.41 3.39 
7B/C 1.00 0.00 0.00 0.00 3.39 
15A/F 1.00 7.69 1.15 3.41 5.08 
11A/D 3.00 5.49 4.60 14.77 6.78 
23B 1.00 2.20 1.15 2.27 10.17 
15B/C 3.00 6.59 12.64 4.55 15.25 
NT+OMNINE 8.00 14.29 11.49 6.82 15.25 
Non-VT13 38.00 64.84 68.97 92.05 83.05 
 
Table 4.3A: The proportion of non-VT13 strains increased from 38.0% of all isolates in pre-
PCV surveillance in 2009, to 83% five years after the introduction of PCV13 in EJ 
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nVT -PA(total %) 2009 (%) 2010 (%) 2011 (%) 2014 (%) 2016 (%) 
11A/D 95.3 4 95.9 25.6 ..5.1 
19B/C 0 05. 0 25.6 0542 
35B 4544 .5. 65. 4543 659. 
15B/C 2519 95. 95.9 9562 45.1 
10A/B .513 65. 0529 9562 0 
23A 053 0 0529 954 4529 
15A/F .513 6 951. 459. 2544 
40 0 0 0 9562 0542 
23B 053 05. .56. 954 .593 
17F 95.4 65. 95.9 9562 0542 
7B/C 0 05. 0 6516 45.1 
NT+OMNINE 45.6 .95. .0 1501 ..5.1 
10B 0 0 0 0 9564 
.6 0 0 0529 9562 0 
16F 95.4 6 0 0 0539 
Total nvt13 sero-
types 
.0566 46 93594 1.514 2.514 
 
Table 4.3B: The proportion of non-VT13 serotypes increased from 39.4% in the pre-PCV period 
(2011) to 65.7% in 2016. 
 
4.6 Parental carriage 
S. pneumoniae carriage among the parents was relatively rare, with 3.3% (n = 157/4696) of    
parents detected as nasopharyngeal carriers in both regions throughout the five study years. In 
2016, S. pneumoniae carriage among the parents was 1.4% (n = 18) of parents seen in both EJ 
(n=1) and PA (n=17). Three of parent strains were belonged to VT7 and two strains were        
belonged to VT13 only in PA. Parental strains that belonged to non-VT13 serotypes detected in 
13 strains in EJ and PA, respectively. All of the 18 parents who were carriers, had a child also 
carrier of the same serotype. Yet, only eight of those parent-child carrier pairs had an identical 
serotype on screening. The small sample size of parental strains did not allow us to assess PCV 
effect on parental carriage or strain distribution. 
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While in Abu Seir and colleagues, the Overall, 18.3% (n = 23) of parent strains belonged to 
VT10    serotypes in both regions. Serotypes 14, 19F and 23F constituted the majority of VT10 
serotypes (73.9%, n = 17). Parental strains that belonged to non-VT13 serotypes constituted 
67.5%  (n = 27) and 72.1% (n = 62) in EJ and PA, respectively. 
Sixty percent of the parents who were carriers, had a child who was also a pneumococcal carrier, 
yet, only 42.7% of those parent-child carrier pairs had an identical serotype on screening. In both 
regions, once PCV was implemented, none of the VT13 carrier parents had a child who carried a 
VT13 strain. 
 EJ PA 
n(%) n(%) 
Parent carriage  49/1616 108/3080 
Strains available for serotyping 41 103 
VT7 7/41 18/103 
VT10 7/41 16/103 
VT13 13/41 26/103 
Non-VT13 28/41 84/103 
Child also carrier of the same sero-
type 
13/41 27/103 
 
Table4.4: pre-vaccine period in EJ included data form 2009 and PA from 2009-2011. post     
vaccine period in EJ included data from 2010-2016 and in PA from 2014-2016 
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4.7Antibiotic use and its resistance 
In EJ, 97/100 samples were tested for penicillin non-susceptible S. pneumoniae (PNSSP) and 
penicillin resistant S. pneumoniae (PRSP) in 2009, and 90/91 in 2010. In 2011 87/87, 2014 
88/88, and in 2016 59/59 samples were tested. Of the samples collected in PA, 192/221 were 
tested in 2009, 197/198 in 2010, 160/160 in 2011, 183/184 in 2014, and 218/218 in 2016 were 
tested for PNSSP and PRSP. All samples were present as no samples were missing in examining 
multi-drug resistant (MDR) isolates in EJ and PA. Between 2009 and 2016, in EJ and PA, there 
was a non-statistically significant decrease in PNSSP prevalence following vaccine implementa-
tion (p=0.2251 and p=0.1864, respectively). In EJ, there was a nearly significant overall decrease 
in PRSP (p=0.0561) and a statistically significant decrease in MDR (p=0.0005) isolates between 
2009 and 2016.  
 
Figure 4.12:Prevalence of isolates number among antibiotic resistant strains. 
 
 
4 
232 
41 
MDR in Child 2016 
NK
NO
YES
Total Number=277 
55 
 
Antibiotic use was reported in about half the children during the three months preceding to 
screening in both districts. About7% of antibiotics were not prescribed by primary care  physi-
cians in both districts as noted from the medical file, but were informed to have been used by the 
parent and were habitually bought over the counter. In 2016 surveillance, out of 277 
S.pneumoniae, 60.6% were did not take any antibiotic, followed by 30.35 carried one antibiotic 
and 7.2% took two and 0.7% were taken there and more from both regions (P=0.00). 
Number of antibiotic use in 
2016 
0 1 2 3+ NK   
Region EJ N 41 13 4 1 0 59 
%  69.5% 22.0% 6.8% 1.7% 0.0% 100.0% 
PA N 127 71 16 1 1 216 
% 58.8% 32.9% 7.4% .5% .5% 100.0% 
Total N 168 84 20 2 3 277 
% 60.6% 30.3% 7.2% .7% 1.1% 100.0% 
 
Table4.5: Number of antibiotic use in 2016 in two region. 
 
Of all S. pneumoniae in 2016, 277 isolates (98.6%) were tested for antibiotic susceptibility. With 
14.8% (41 strains) were MDR in both EJ and PA. PNSSP prevalence with 56% in both EJ and 
PA, and 19.5% were PRSP in both regions. Of all S. pneumoniae, 829 isolates (96.3%) were   
tested for antibiotic susceptibility. PNSSP prevalence was extremely high in the first study year, 
with 83% in both EJ and PA pre-vaccine introduction. This is in Daana work(Daana et al. 2015) 
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Chapter Five:  
Discussion, Conclusions, Limitations and Recommendations 
 
This Comparison of PCVs study was conducted to investigate the impact of vaccine of               
S. pneumoniae among Palestinians children. The findings of this study provide an estimate for 
the prevalence of several of pneumococcal serotypes that have not been previously considered. 
This chapter highlights the major findings and the recommendations and limitations of the study. 
5.1 Discussion 
Vaccination and the type of vaccine is an important issue for decreasing the prevalence of      
diseases caused by S. pneumonia. In this study, we conducted an additional surveillance that was 
done in 2016, following the introduction of PCV10 in 2011 and to the previously unvaccinated 
populations.  
 Thus we evaluated PCVs on pneumococcal carriage among children and their parents and the 
effects of the different vaccination programs. 
In our study, we have shown the effects of the pneumococcal conjugate vaccine on pneumococ-
cal carriage among children, as well as the effects of the examined vaccination      programs on 
serotype distribution in two closely related populations living in EJ, and PA throughout 2009-
2016. Here, we conducted an additional surveillance in 2016, following the introduction of 
PCV10 and PCV7/13 to the previously unvaccinated population and to the     population that 
were vaccinated. 
 The main effect observed in these two regions was that following the introduction of the    
pneumococcal conjugate vaccines, the prevalence of VT serotypes reduced until eventually they 
were nearly eliminated. However, this decrease did not result in an overall decrease in the       
carriage of S. pneumoniae since serotype replacement followed in the two regions, both in the    
Palestinian Authority (PA) as well as the low socio-economic level populations from East       
Jerusalem (EJ) regardless of whether PCV10 or PCV7/13 was introduced.  
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5.2 S. pneumoniae Carriage 
For the prevalence of carriage of pneumococci, the only significant change was observed in EJ in 
2016, when pneumococcal carriage decreased significantly as compared to all previous years 
2009, 2010, 2011 and 2014. The decline in S. pneumoniae carriage in EJ goes with the findings 
of an active surveillance study done in EJ in 2009, which compared S. pneumoniae   carriage in a 
middle-class EJ population and a low socio-economic level EJ population. Both PCV7 and 
PCV13 uptake were high, reaching~90% by July 2012 and December 2013, respectively. That 
study determined that all-pneumococcal carriage rates significantly declined by approximately  
10%, from 54.3% in the early-PCV7 period, to 49.1% in the PCV13 impact period with a       
significant decline detected in the EJ population, and a mild decline perceived in the EJ       
population following PCV7 and later PCV13 implementation (Ben-Shimol et al. 2016). This dif-
ference in carriage was attributed to overcrowding and large families, similar to the situation ob-
served in EJ. Unlike EJ, in PA, a significant variation was not observed in overall pneumococcal 
carriage between 2009 and 2016 (~32% on average), and this is probably due to the difference in 
timing of corresponding vaccine implementations in EJ and PA. The trend in the prevalence of S. 
pneumoniae carriage in PA is predicted to follow the trend observed in EJ 7 years after vaccine 
implementation due to similar background factors shared in EJ and PA. Therefore, a longer    
follow-up study is recommended.  
The higher effectiveness and cost-effectiveness of PCV13 compared to PCV10 was reported in 
few studies, one study reported 97% effectiveness against VT-IPD for PCV10, but 86% effec-
tiveness for PCV13 (Deceuninck et al. 2015). 
while other studies (Domingues et al. 2014), showed no differences between the two vaccines. 
So there is disagreement over the advantage of PCV13 compared to PCV10, especially regarding 
the effect on 19A, that arise following PCV10 in some studies but decrease in other. This may be 
due to differences in the study design, different outcomes assessed (carriage,IPD, etc.), or differ-
ent vaccine coverage. However, this may be due to differences in the circulating clones in the 
different geographic regions. 
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The explanation for the relatively stable prevalence of S. pneumoniae carriage despite the       
introduction of an effective vaccine is that while VT strains are affected by vaccination, they are 
replaced by non-VT strains. This phenomenon of serotype replacement has been pronounced in 
other geographical areas and has been discussed (Flasche et al. 2011). 
 
 By the end of our study period in 2016 and after PCV7/13 had been implemented in  EJ and 
PCV10 in PA, similar non-VT serotypes emerged in two regions, including serotypes 10, 11A/D, 
15A/F, 15B/C, 23A, 23B, and 7B/C. 
 5.3 PCV Impact on Serotype Distribution 
A trend was observed in EJ where VT7 strains declined from 47% of all serotypes in 2009, prior 
to vaccine implementation, to 5.0% of all serotypes in 2014, post vaccine implementation. By 
2016, we observed a slight non-significant increase in the prevalence of VT7 strains; by that 
point they account for 8.0% of all isolates in EJ. Additionally, a similar trend was observed in 
PA, where PCV10 was implemented where the prevalence of VT7 strains was approximately 
40.8% prior to vaccine administration and decreased to 16.2% by 2016, 5 years after vaccine im-
plementation. 
 
 According to previous studies, serotypes 1, 4, 5, 7F, 8, 12F, 14, 18C, and 19A are prospective to 
cause IPD. Although serotypes 1 and 19A are the predominant causes of IPD, serotype 14 still 
one of the most common etiologic agents of non bacteremic pneumonia in adults, even after 
PCV7 introduction. Serotypes 1, 3, and 19A pneumococci are likely to cause empyema and   
hemolytic uremic syndrome (J. Y. Song, Nahm, and Moseley 2013).  
The observed increase in the prevalence of VT7 strains in EJ during the last year of this study 
was surprising. This increase can be mainly attributed to the reappearance of serotype 19F,     
although it is covered by the 3 PCVs, and its prevalence in the population was expected to      
further decrease with ongoing vaccination. Supporting to our findings, a similar observation was 
reported in Taiwan, where serotype 19F persisted in the population several years following 
PCV13 implementation (Cho et al. 2017). The persistence of serotype 19F may be due to its in-
vasiveness, higher colonization rate, and advantages conferred by its antibiotic resistance proper-
ties.  
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Over the course of this study, serotypes 1, 5, and 7F were not detected in the populations in EJ, 
or PA. This is not surprising, since these serotypes are rarely carried, highly virulent and         
associated with epidemics.  
When comparing the impact of PCV10 with that of PCV13, the most interesting finding is the 
impact on the serotypes covered by one vaccine, but not the other, (i.e., serotypes 3, 6A, and 19A 
which are referred in our study as VT13-10 strains). In EJ, a significant decline was observed in 
the prevalence of VT13-10 between 2009 and 2010, following PCV7 implementation, and may 
also be attributed to the decrease observed in serotype 6A. Following implementation of PCV13 
in EJ, where the proportion of detected VT13-10 fell to 4.55% by 2014 from 8.79% in 2010.   
However, the prevalence of VT13-10 increased in EJ to 3.39% by 2016. This slight decrease is 
likely due to a decrease in the prevalence of serotype 3. In PA where PCV10 was introduced, the 
proportion of VT13-10 strains in the pre-PCV10 era, consisted of 18.75% in 2011, similar to 
vaccine rates in 2016. This similarity due to the increase in the prevalence of serotype 19A. 
In that study (Ben-Shimol et al. 2016), a respective declines for PCV7, 6A and additional PCV13 
serotypes carriage rates were 76%, 90% and 66%. In contrast, non-PCV13 serotypes carriage 
rates increased significantly throughout the study, Interestingly, the comparison of the impact of 
the different PCVs on serotypes covered by one vaccine, but not the other (serotypes 3, 6A and 
19A). Serotype 6A has been repeatedly reported to decrease following PCV7 or PCV10 imple-
mentation (J. Y. Song, Nahm, and Moseley 2013). 
This is due to cross-protection by 6B in PCV7/PCV10. Serotype 19A, which is not included in 
either PCV7or PCV10, could similarly be cross-protected by 19F which is included in both these 
vaccines. However, only modest protection has been suggested (Hausdorff, Hoet, and 
Schuerman 2010). In EJ, following PCV10 implementation, the prevalence of VT13-10 strains 
decreased to 10.33% in 2014.  This surprising effect was due to a significant decrease in both 
serotypes 6A and 19A, within 3 years of PCV implementation. This decrease could potentially 
be explained by cross-reaction of the PCV10 effect on 6B and 6A and similarly on 19F and 19A. 
While cross-reaction between 6A and 6B has been repeatedly reported (Whitney et al. 2006), 
there is much debate about the effect of PCV10 on 19A. (Prymula et al. 2006). 
 Unlike PCV10, the use of PCV7 has been repeatedly shown to be followed by increases in 19A 
and no cross-reactivity is assumed for this vaccine (Moore et al. 2008). 
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PCV7 introduction in many countries, led to emergence of serotype 19A both in carriage and in 
IPD (Isturiz et al. 2017),that did not observe emergence of 19A in EJ after PCV7 and before 
PCV13 was implemented. Similarly a nationwide IPD surveillance study in Israel did not report 
19Aincrease following PCV7 introduction among children or adults (Regev-Yochay et al. 2017). 
A plausible explanation could be the rapid transition from PCV7 to PCV13 within less than two 
years in Israel, or a different clonal background distribution. In contrast to PCV7, the impact of 
PCV10 on serotype 19A is much more debated. Several studies reported PCV10 effectiveness 
against serotype 19A (Wagenvoort et al. 2016).  
Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal  Conju-
gate Vaccine, the Netherlands .Emerging infectious diseases. while other studies reported    
emergence of serotype 19A following PCV10 introduction (Huang et al. 2009). The changing 
epidemiology of invasive pneumococcal disease at a tertiary children‘s hospital through the 7-
valent pneumococcal conjugate vaccine era: a case for continuous surveillance (Isaacman, 
McIntosh, and Reinert 2010).  
 
Interestingly, in PA, the decrease in VT13-10 strains was temporally transient and likely due to  
changes after PCV10 implementation. By 2016, the prevalence of VT13-10 strains in that region 
had increased to 18.06%, and this increase was mainly due to an increase in serotype 19A.  Our 
results were consistent with other studies that have compared the effects of PCV7, PCV10, and 
PCV13. In our study, PCV10 does not appear to be as effective as PCV13 in targeting serotype 
19A, suggesting that PCV10 does not provide direct immunity against serotype 19A (Isturiz et 
al. 2017; Wysocki et al. 2009). These results emphasize the need to continue and monitor the 
changing epidemiology and serotype distribution of S. pneumoniae  following different vaccina-
tion policies. However, it is important to note that these are only short-term (three years) obser-
vations, and longer follow-up is mandatory to determine the long-term effect of PCV10 on sero-
type 19A. Serotype 3 is one of the three additional serotypes not included in PCV10, is unique in 
many aspects, heavily encapsulated with a mucoid phenotype, highly  resistant to phagocytosis. 
While some have suggested that despite this it is not invasive (Brueggemann et al. 2004). 
Many studies from different geographical regions have reported ineffectiveness of PCV13 
against serotype 3 (Naucler et al. n.d.). We show a nearly significant increase in serotype 3     
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following PCV13 implementation in EJ (p = 0.05) and no change after PCV10 implementation in 
PA. Whether serotype 3 will eventually decrease in a longer follow-up is yet to be observed. 
Serotype 6C, a non-VT serotype, is biochemically different from serotype 6A and 6B, but 
serologically similar to serotype 6A (Park et al. 2007). Serotype 6C was reported to increase in      
prevalence in carriage and in IPD cases following PCV7 implementation in the United States 
(Millar et al. 2010). Cross protection between serotype 6A in PCV13 and 6C has been reported 
(Cooper et al. 2011).  
 
In EJ, following PCV7 implementation, the prevalence of serotype 6C increased in 2010 
(4.4%), while following PCV13 implementation, the prevalence of serotype 6C decreased and 
was eliminated by 2016 (0.0%), similar to the trend reported in the United States. Unlike 
 EJ, in PA, the prevalence of serotype 6C increased following PCV10 implementation. This was 
in line with our expectations based on the fact that cross protection against serotype 6C was not 
seen for PCV10 in a cross-sectional study conducted in Brazil in 2010 and 2013 
(M.-C. C. de Brandileone et al. 2016). 
Serotype replacement is a common phenomenon in which non-VT serotypes emerge and 
replace VT serotypes with geographic variability(Weinberger, Malley, and Lipsitch 2011). 
The emerging serotypes we observed following the two different vaccination policies were    
nearly similar. In 2016 surveillance, In EJ, the most notable emerging non-VT serotypes were 
15B/C and 23B and in PA they were 11A/D, 15B/C, 23A, 15A/F, 7B/C and 10B.  while in 2014, 
In EJ, the most notable emerging non-VT serotypes were 11A/D, 19B/C, 25/38, 40, 21, 9N/L 
and 12F and in PA they were 19B/C, 40, 23A and 7B/C(Abu Seir et al. 2018). A study in              
Massachusetts, USA reported that several years following PCV7 implementation, serotypes 19A, 
6A, 15B/C, 35B,and 11A emerged (Huang et al. 2009). 
In Northern Japan, serotypes 15A, 23A, 11A, 10A and 35B accounted for the majority of non-
VT13 serotypes after the introduction of PCV13 (Kawaguchiya et al. 2016)Serotype 6C was 
shown to decline after PCV13 introduction but not PCV7 or PCV10 (M. C. de C. Brandileone et 
al. 2016).Interestingly, we observed emergence of 6C following PCV7 implementation, but a 
decrease after PCV13  in EJ, but increased after PCV10 implementation in PA. 
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5.4 Antibiotic Resistance  
Since antibiotic resistance was relatively common among VT strains, and most of the observed 
antibiotic-resistant strains were VT strains, it was important to note that more than 60% did not 
use antibiotics. In 2009-2011 study (Daana et al. 2015),  antibiotic resistance in the pre-vaccine 
period was wide spread in both EJ and PA, similar to observed rates in EJ populations 
(Greenberg et al. 2008). but much higher than reported in USA, Europe or Israeli Jewish popula-
tions (Huang et al. 2009), where approximately 10% PRSP and 35% PNSSP have been reported. 
This may be expected considering the high antibiotic use reported in our population. In 2016, 
PNSSP prevalence with 56% in both EJ and PA, and 19.5% were PRSP in both regions. With 
14.8% (41 strains) were MDR in both EJ and PA. Since most antibiotic resistant strains in the 
pre-PCV  period belonged to VT serotypes, it was not surprising that the introduction of 
PCV7/PCV13 and PCV10 resulted in decline in resistant-VT strains. Nevertheless, this increase 
in antibiotic resistance may serve as a window of opportunity to enhance careful antibiotic use 
that may be required together with PCV pressure to produce along-lasting reduction in antibiotic 
resistant pneumococci. The prevalence of antibiotic-resistant S. pneumoniae has increased 
worldwide and might be related to the spread of pediatric pneumococcal serotypes (6A, 6B, 9V, 
14, 15A, 19F, 19A, and 23F). After the introduction of PCV7, the prevalence of PCV7 serotypes 
and serotype 6A were reduced and subsequently replaced by non-PCV7 serotypes, including 
serotype 19A. Although Spain 23F-ST81 and Spain6B-ST90 were well-established multidrug-
resistant clones in the 1980s and 1990s, their prevalence decreased after the introduction of 
PCV7. 
Parental nasopharyngeal pneumococcal carriage was rare in our population, this could be due to 
our determination of the carriage via nasopharyngeal swabbing, while recent reports suggested 
higher yield in adults when swabbing both pharynx and nasopharynx or adding  salivary testing 
(Trzciński et al. 2013). 
In 2016, only 45.3% of those parent child co-carrier pairs had an identical serotype, While only 
42.7% of those parent child co-carrier pairs had an identical serotype (Rania et al., 2018).   
Similar dis concordance was previously reported among adults in Israel, where intra-familial 
transmission could not be demonstrated (Regev‐ Yochay, Raz, et al. 2004). 
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Children were shown to carry pneumococcal strains for months, while adults typically carry 
pneumococci for only very short durations (Shak, Vidal, and Klugman 2013),Yet, this does not 
essentially explain the relative dis-concordance of serotypes between children and their parents. 
The difference between serotypes carried by children‘s and their parents‘ could be due to the dif-
ference of the direct PCV impact and the indirect (herd effect) impact, on their parents, particu-
larly the potential time lag of the effects. 
 
 
5.5 Study Limitations 
It is important to note that this study was an observational study and not a controlled intervention 
trial. So the following points we considered as limitation to our study. First: the policies of     
vaccination were introduced at different times, PCV7/13 in 2009/2010 in EJ, andPCV10 in 2011 
in PA. Those differences between the private clinics of PA and EJ could be an  additional     con-
cern, although the socioeconomic status of the people who visit those private clinics is     similar 
to that of the population served in EJ. Second, while the two compared populations are closely 
related, they differed in several variables that were adjusted. For our study did not      consider 
possible mixing or cross-contamination between EJ and PA due to the mixing of the populations 
of those regions, but such mixing is most likely limited due to existing barriers. Third, the over-
all carriage in the children was relatively low, probably due to the ‗off season‘ periods we chose, 
i.e. spring and summer, when carriage of pneumococci is lower. This was   intentional in order to 
overcome seasonal variability, but limited the power to detect some       differences.  
5.6 Conclusion 
In conclusion, following the introduction of PCV, the overall prevalence of carriage did not 
change significantly, but the prevalence of vaccine-type serotypes decreased and those serotypes 
were nearly eliminated, regardless of which PCV was used. Despite the short follow-up interval 
after implementation of PCV13 in EJ, a dramatic decrease in the VT13 serotypes (including    
serotypes 6A and 19A but not serotype 3) was observed in EJ. While implementation of PCV10 
in PA shows a dramatic increase in VT13 serotypes in PA. Replacement by non-VT13 was also 
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observed in both populations regardless of the vaccination used. Longer follow up is needed to 
compare the long-term effects. 
 
5.7 Recommendations 
Our study highlights the need for large population-based reconciliation studies. Further studies 
should be conducted on the PCV. Moreover, in addition to NVT, the evaluation of PCVs lead to 
decreased deaths of children. This study is short follow-up interval that only reports the short-
term impact of the vaccines, so to assess the long-term differences between the vaccines, longer 
follow-up is needed. Educational and awareness programs are recommended for both physicians 
and medical laboratories for appropriate and reliable diagnosis and appropriate antibiotic treat-
ment decisions. This can help reduce the development of more complex antibiotics 
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Chapter Seven:  
Appendices 
Table 6.1: Frequency of VT Serotypes in PA 
  PA 
Serotype 2009 2010 2011 2014 2016 p-trend  
  sp (n=223) sp (n=200) sp (n=160) sp (n=184) sp (n=216)   
  
N 
% 
N 
% 
N 
% 
N 
% 
N 
% 
2009-
2014 
19F 43 27 25 11 10 P = 0.000 
  19.28% 13.50% 15.63% 5.98% 4.63%   
14 19 9 13 13 10 P = 0.291 
  8.52% 4.50% 8.13% 7.07% 4.63%   
6B 8 14 8 2 4 P = 0.030 
  3.59% 7.00% 5.00% 1.09% 1.85%   
23F 16 18 16 4 7 P = 0.007 
  7.17% 9.00% 10.00% 2.17% 3.24%   
9V 4 6 2 3 3 
 P = 
0.473 
  1.79% 3.00% 1.25% 1.63% 1.39%   
4 1 1 0 2 1 P = 0.726 
  0.45% 0.50% 0.00% 1.09% 0.46%   
18C 0 0 2 0 0 P = 0.977 
  0.00% 0.00% 1.25% 0.00% 0.00%   
Total VT7 91 75 66 35 35 P = 0.000 
  40.81% 37.50% 41.25% 19.02% 16.20%   
7F 0 1 0 0 0 P = 0.511 
  0.00% 0.50% 0.00% 0.00% 0.00%   
1 2 0 0 0 0 ND 
  0.90% 0.00% 0.00% 0.00% 0.00%   
5 0 0 1 0 0 P = 0.983 
  0.00% 0.00% 0.63% 0.00% 0.00%   
Total VT10 2 1 1 0 0 P = 0.098 
  0.90% 0.50% 0.63% 0.00% 0.00%   
6A 21 25 17 9 13 P = 0.024 
  9.42% 12.50% 10.63% 4.89% 6.02%   
19A 5 9 6 2 19   
  2.24% 4.50% 3.75% 1.09% 8.80%   
3 4 5 7 7 7 P = 0.262 
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  1.79% 2.50% 4.38% 3.80% 3.24%   
Total VT13 30 39 30 18 39 P = 0.917 
  13.45% 19.50% 18.75% 9.78% 18.06%   
All VT 123 115 97 53 74 P = 0.000 
 
Table 6.2: Frequency of non-VT (NVT) Serotypes in PA 
  Non-VT13 SEROTYPES                     PA 
  2009 2010 2011 2014 2016 p-trend  
  sp (n=223) sp (n=200) sp (n=160) sp (n=184) sp (n=216)   
  
N 
% 
N 
% 
N 
% 
N 
% 
N 
% 
2009-
2014 
11A/D 8 8 5 12 25 
P = 
0.000 
  3.59% 4.00% 3.13% 6.52% 11.57%   
19B/C 0 1 0 12 1 
P = 
0.014 
  0.00% 0.50% 0.00% 6.52% 0.46%   
25/38 0 2 1 4 0 
P = 
0.569 
  0.00% 1.00% 0.63% 2.17% 0.00%   
35B 10 3 4 9 5 
P = 
0.706 
  4.48% 1.50% 2.50% 4.89% 2.31%   
15B/C 15 7 5 6 9 
P = 
0.210 
  6.73% 3.50% 3.13% 3.26% 4.17%   
10A/B 4 5 1 6 0 
P = 
0.266 
  1.79% 2.50% 0.63% 3.26% 0.00%   
12F 0 0 1 6  0 
P = 
0.110 
              
22F 0 1 1 2 2 
P = 
0.150 
  0.00% 0.50% 0.63% 1.09% 0.93%   
23A 2 0 1 7 10 
P = 
0.000 
  0.90% 0.00% 0.63% 3.80% 4.63%   
15A/F 4 4 6 8 14 
P = 
0.004 
  1.79% 2.00% 3.75% 4.35% 6.48%   
40 0 0 0 6 1 P = 
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0.035 
  0.00% 0.00% 0.00% 3.26% 0.46%   
21 2 1 0 1 2 
 P = 
0.959 
  0.90% 0.50% 0.00% 0.54% 0.93%   
9N/L 1 3 1 1 4 
P = 
0.354 
  0.45% 1.50% 0.63% 0.54% 1.85%   
6C 1 3 2 0 5 
P = 
0.273 
  0.45% 1.50% 1.25% 0.00% 2.31%   
23B 2 1 2 7 3 
P = 
0.136 
  0.90% 0.50% 1.25% 3.80% 1.39%   
17F 7 5 5 6 1 
P = 
0.150 
  3.14% 2.50% 3.13% 3.26% 0.46%   
7B/C 0 1 0 5 9 
P = 
0.000 
  0.00% 0.50% 0.00% 2.72% 4.17%   
8 0 2 0 1 0 
P = 
0.722 
  0.00% 1.00% 0.00% 0.54% 0.00%   
9A 1 0 0 2 0 
P = 
0.971 
  0.45% 0.00% 0.00% 1.09% 0.00%   
9B 0 0 1 0 0 
P = 
0.983 
  0.00% 0.00% 0.63% 0.00% 0.00%   
NT+OMNINE 19 27 16 13 25 
P = 
0.940 
  8.52% 13.50% 10.00% 7.07% 11.57%   
10A 0 0 0 0 1 
P = 
0.168 
  0.00% 0.00% 0.00% 0.00% 0.46%   
10B 0 0 0 0 7 
P = 
0.000 
  0.00% 0.00% 0.00% 0.00% 3.24%   
10B/C 0 0 0 1 0 
P = 
0.485 
  0.00% 0.00% 0.00% 0.54% 0.00%   
10F/C 2 1 0 0 0 
P = 
0.054 
  0.90% 0.50% 0.00% 0.00% 0.00%   
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12 0 0 1 6 0 
P = 
0.110 
  0.00% 0.00% 0.63% 3.26% 0.00%   
13 0 0 0 0 4 
P = 
0.006 
  0.00% 0.00% 0.00% 0.00% 1.85%   
13/47 3 3 2 4 0 
P = 
0.362 
  1.35% 1.50% 1.25% 2.17% 0.00%   
16F 7 4 0 0 2 
P = 
0.010 
  3.14% 2.00% 0.00% 0.00% 0.93%   
18A/B/F 1 1 1 1 0 
P = 
0.524 
  0.45% 0.50% 0.63% 0.54% 0.00%   
24 3 1 0 0 2 
P = 
0.434 
  1.35% 0.50% 0.00% 0.00% 0.93%   
28 4 0 2 2 2 
P = 
0.715 
  1.79% 0.00% 1.25% 1.09% 0.93%   
29 0 0 0 0 0 ND 
  0.00% 0.00% 0.00% 0.00% 0.00%   
31 2 0 2 0 3 
 P = 
0.569 
  0.90% 0.00% 1.25% 0.00% 1.39%   
32 1 0 0 0 0 ND 
  0.45% 0.00% 0.00% 0.00% 0.00%   
33A/B/C 1 0 0 1 0 
 P = 
0.652 
  0.45% 0.00% 0.00% 0.54% 0.00%   
33F 2 0 1 1 3 
P = 
0.409 
  0.90% 0.00% 0.63% 0.54% 1.39%   
34 1 0 2 0 0 
P = 
0.454 
  0.45% 0.00% 1.25% 0.00% 0.00%   
35AC/42 0 0 0 0 2 
 P = 
0.051 
  0.00% 0.00% 0.00% 0.00% 0.93%   
35F47F 0 0 1 2 0 
P = 
0.412 
  0.00% 0.00% 0.63% 1.09% 0.00%   
36/37 2 0 0 1 0 P = 
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0.254 
  0.90% 0.00% 0.00% 0.54% 0.00%   
39 0 0 0 1 0 ND 
  0.00% 0.00% 0.00% 0.54% 0.00%   
42 4 0 0 0 0 ND 
  1.79% 0.00% 0.00% 0.00% 0.00%   
43/44/46 1 0 0 1 0 
P = 
0.652 
  0.45% 0.00% 0.00% 0.54% 0.00%   
7 0 0 0 0 0 ND 
  0.00% 0.00% 0.00% 0.00% 0.00%   
7A 1 0 0 0 0 ND 
  0.45% 0.00% 0.00% 0.00% 0.00%   
22A 1 0 0 0 0 ND 
  0.45% 0.00% 0.00% 0.00% 0.00%   
17A 0 0 0 3 0 
P = 
0.226 
  0.00% 0.00% 0.00% 1.63% 0.00%   
 Total 
 non-VT13 
SEROTYPES  
112 84 63 132 142 
  
  50.22% 42.00% 39.38% 71.74% 65.74% 
P = 
0.000  
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Table 6.3: Frequency of VT Serotypes in EJ  
 
  East Jerusalem 
  2009 2010 2011 2014 2016 p-trend  
  sp (n=100) sp (n=91) sp (n=87) sp (n=88) sp (n=59)   
  
N 
% 
N 
% 
N 
% 
N 
% 
N 
% 
2009-2016 
19F 16 9 5 0 2 P = 0.000 
  16% 9.89% 5.75% 0.00% 3.39%   
14 9 4 3 2 2 P = 0.045 
  9% 4.40% 3.45% 2.27% 3.39%   
6B 13 9 7 0 1 P = 0.000  
  13% 9.89% 8.05% 0.00% 1.69%   
23F 6 1 5 2 2 P = 0.480 
  6% 1.10% 5.75% 2.27% 3.39%   
9V 1 0 1 1 0  P = 0.866 
  1% 0.00% 1.15% 1.14% 0.00%   
4 0 0 0 0 1 P = 0.108 
  0 0.00% 0.00% 0.00% 1.69%   
18C 2 1 0 0 0 P = 0.063 
  2% 1.10% 0.00% 0.00% 0.00%   
Total VT7 47 24 21 5 8 P = 0.000 
  47% 26.40% 24% 5.70% 13.50%   
7F 0 0 0 0 0 ND 
  0 0.00% 0.00% 0.00% 0.00%   
1 0 0 0 0 0 ND 
  0 0.00% 0.00% 0.00% 0.00%   
5 1 0 0 0 0 ND 
  1% 0.00% 0.00% 0.00% 0.00%   
Total VT10 1 0 0 0 0 ND 
  1% 0.00% 0.00% 0.00% 0.00%   
6A 11 5 4 0 0 P = 0.000  
  11% 5.49% 4.60% 0.00% 0.00%   
19A 3 2 1 1 0 P = 0.119 
  3% 2.20% 1.15% 1.14% 0.00%   
3 0 1 1 3 2 P = 0.040 
  0 1.10% 1.15% 3.41% 3.39%   
Total VT13 14 8 6 4 2 P = 0.006  
  14.00% 8.79% 6.90% 4.55% 3.39%   
All VT 62 32 27 9 10 P = 0.000  
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Table 6.4: Frequency of non-VT (NVT) Serotypes in EJ   
  Non-VT13 SEROTYPES                    EJ 
Serotype 2009 2010 2011 2014 2016 p-trend  
  sp (n=100) sp (n=91) sp (n=87) sp (n=88) sp (n=59)   
  
N 
% 
N 
% 
N 
% 
N 
% 
N 
% 
2009-
2014 
11A/D 3 5 4 13 4 P = 0.027 
  3.00% 5.49% 4.60% 14.77% 6.78%   
19B/C 0 0 4 7 0 
 P = 
0.040 
  0.00% 0.00% 4.60% 7.95% 0.00%   
25/38 0 3 1 6 0 
 P = 
0.243 
  0.00% 3.30% 1.15% 6.82% 0.00%   
35B 4 2 7 6 1 P = 0.738 
  4.00% 2.20% 8.05% 6.82% 1.69%   
15B/C 3 6 11 4 9 
 P = 
0.028 
  3.00% 6.59% 12.64% 4.55% 15.25%   
10A/B 2 1 1 4 0 P = 0.876 
  2.00% 1.10% 1.15% 4.55% 0.00%   
12F 0 1 0 3  0 P = 0.305 
  0.00% 1.10% 0.00% 3.41% 0.00%   
22F 0 0 0 3 0 
 P = 
0.128 
  0.00% 0.00% 0.00% 3.41% 0.00%   
23A 1 3 2 3 2 P = 0.349 
  1.00% 3.30% 2.30% 3.41% 3.39%   
15A/F 1 7 1 3 3 
  P = 
0.565 
  1.00% 7.69% 1.15% 3.41% 5.08%   
40 0 0 0 2 1 P = 0.052 
  0.00% 0.00% 0.00% 2.27% 1.69%   
21 0 0 0 2 0 P = 0.214 
  0.00% 0.00% 0.00% 2.27% 0.00%   
9N/L 0 0 2 2 1 P = 0.101 
  0.00% 0.00% 2.30% 2.27% 1.69%   
6C 0 4 3 2 0 P = 0.961 
  0.00% 4.40% 3.45% 2.27% 0.00%   
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23B 1 2 1 2 6 P = 0.008  
  1.00% 2.20% 1.15% 2.27% 10.17%   
17F 4 4 4 0 1 P = 0.128 
  4.00% 4.40% 4.60% 0.00% 1.69%   
7B/C 1 0 0 0 2 P = 0.272 
  1.00% 0.00% 0.00% 0.00% 3.39%   
8 0 0 0 0 0 ND 
  0.00% 0.00% 0.00% 0.00% 0.00%   
9A 0 0 0 1 0 ND 
R 0.00% 0.00% 0.00% 1.14% 0.00%   
9B 0 0 1 0 0 ND 
  0.00% 0.00% 1.15% 0.00% 0.00%   
NT+OMNINE 8 13 10 6 9 P = 0.632 
  8.00% 14.29% 11.49% 6.82% 15.25%   
10A 0 0 0 0 2 P = 0.023 
  0.00% 0.00% 0.00% 0.00% 3.39%   
10B 0 0 0 0 1 P = 0.108 
  0.00% 0.00% 0.00% 0.00% 1.69%   
10B/C 0 0 0 1 0 ND 
  0.00% 0.00% 0.00% 1.14% 0.00%   
10F/C 0 0 0 1 0 ND 
  0.00% 0.00% 0.00% 1.14% 0.00%   
12 0 1 0 3 0 P = 0.031 
  0.00% 1.10% 0.00% 3.41% 0.00%   
13 0 0 0 0 1 P = 0.108 
  0.00% 0.00% 0.00% 0.00% 1.69%   
13/47 1 1 1 1 0 
 P = 
0.660 
  1.00% 1.10% 1.15% 1.14% 0.00%   
16F 1 1 0 1 1 P = 0.769 
  1.00% 1.10% 0.00% 1.14% 1.69%   
18A/B/F 0 0 1 0 1 P = 0.214 
  0.00% 0.00% 1.15% 0.00% 1.69%   
24 1 0 1 2 0 
  P = 
0.769 
  1.00% 0.00% 1.15% 2.27% 0.00%   
28 2 2 0 1 1 P = 0.942 
  2.00% 2.20% 0.00% 1.14% 1.69%   
29 1 0 0 1 0 P = 0.756 
  1.00% 0.00% 0.00% 1.14% 0.00%   
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31 0 0 1 0 0 P = 0.884 
  0.00% 0.00% 1.15% 0.00% 0.00%   
32 0 0 0 0 0 ND 
  0.00% 0.00% 0.00% 0.00% 0.00%   
33A/B/C 0 0 0 0 0 ND 
  0.00% 0.00% 0.00% 0.00% 0.00%   
33F 2 1 3 1 1 
 P = 
0.917 
  2.00% 1.10% 3.45% 1.14% 1.69%   
34 1 1 0 1 0 P = 0.554 
  1.00% 1.10% 0.00% 1.14% 0.00%   
35AC/42 0 0 0 0 1 P = 0.108 
  0.00% 0.00% 0.00% 0.00% 1.69%   
35F47F 0 0 0 1 0 
   P = 
0.381 
  0.00% 0.00% 0.00% 1.14% 0.00%   
36/37 0 0 0 0 1 P = 0.108 
  0.00% 0.00% 0.00% 0.00% 1.69%   
39 0 0 0 0 0 ND 
  0.00% 0.00% 0.00% 0.00% 0.00%   
42 0 2 0 0 0 P = 0.408 
  0.00% 2.20% 0.00% 0.00% 0.00%   
43/44/46 0 0 0 1 0 
   P = 
0.381 
  0.00% 0.00% 0.00% 1.14% 0.00%   
7 0 0 0 0 0 ND 
  0.00% 0.00% 0.00% 0.00% 0.00%   
7A 0 0 0 0 0 ND 
  0.00% 0.00% 0.00% 0.00% 0.00%   
22A 1 0 0 0 0 ND 
  1.00% 0.00% 0.00% 0.00% 0.00%   
17A 0 0 1 0 0 
 P = 
0.408 
  0.00% 0.00% 1.15% 0.00% 0.00%   
 Total 
 non-VT13 
SEROTYPES  
38 59 60 81 49 
  
Non-VT13 38.00% 64.84% 68.97% 92.05% 83.05% P = 0.001  
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Freezing Thawing Protocol for S. pneumonia isolates 
1. Fresh grown colonies of S. aureus should be frozen in 25% glycerol/BHI at -
80
o
C. For short durations (up to 1 week freezing in -4
o
c is adequate): 
a. Label the side of the eppendorf tube with the same code that was given to 
the patient in the original sampling laboratory and also use a new serial 
number for each patient and label the cap of the eppendorf 
b. Weigh 37.8 gram of brain heart infusion (BHI) and put in a graduated cyl-
inder 
c. Add ddH2O till 750ml 
d. Stir on a stirrer till the solution is homogenous 
e. Add 250ml of pure glycerol and 
f. Mix well and autoclave 
g. Aliquote 1 ml of the freezing solution in a screw capped sterile eppendorf 
tubes 
h. Freeze to be used when the bacteria is available, then thaw 
i. Swab as much as possible of the pure fresh grown isolates and mix with 
the freezing solution, squeeze on the edges of the Eppendorf tube . 
j. Freeze at -80oC. For short durations (up to 1 week freezing in -20oC is ad-
equate( 
k. Enter all patient data into your computerized system by taking the bar 
code of the label and then enter the serial number manually, box number, 
freezer number, shelf number, then all patients data and susceptibility re-
sults…(according to the built patient sheet)
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Thawing Protocol for S. pneumonia isolates 
 
1. Take out the required frozen samples from the  -80oC freezer according to the 
freezing numbers. 
2. Open the box in the hood, open the Eppendorf carefully and don‘t cause contami-
nation (perform it quickly otherwise put the samples on ice to prevent complete 
thawing) 
3. Streak a bit of the frozen bacterial on blood agar (half a plate or use one plate for 
three samples). 
4. Incubate at 37oC for 24hrs to proceed in serotyping and PCRs 
5. In case of contamination, try to get a pure culture by streaking a single colony on 
blood agar (you can use blood agar with gentamycin for Streptococcus pneumoni-
ae) 
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Freeze Tube Protocol for S. pneumonia isolates 
 
 
1. Add 37.8 gram of brain heart infusion (BHI). 
2. Dissolve BHI with 1 letter of dH2O. 
3. Add 333.33 ml glycerol to solution. 
4. Put in autoclave. 
 
 This protocol for 1 liter,1000 freeze tube approximately. 
 If we need less than 1L can we prepare about 500 ml dH2O with 18.9 g of BHI and 
166.66 ml glycerol. 
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Protocol for culturing Streptococcus pneumonia 
1. Label all of the required plates and eppendorf tubes with the same original patient green 
code that was given in the original laboratory 
2. Subculture colonies on 3 blood agar plates for identification and susceptibility testing 
(AST) 
a. Two Blood agar for antibiotic susceptibility testing as the following protocol: 
i. Put 1-2ml Brain Heart Infusion Broth in a clear tube 
ii. Take one small colony of Streptococcus pneumonia, dip in the tube and 
mix till you get the same turbidity as McFarland standard tube 
iii. Streak on two plates of blood  agar and add the following antibiotics:  
1. Plate I: cefoxitin, erythromycin, clindamycin, gentamicin and 
TMP/SMX (Trimethoprim-sulfamethoxazole) 
2. Optochin disc diffusion and strips of penicillin and ceftriaxone  
3. Plate II tetracycline, rifampin, fusicid acid, ofloxacin and vanco-
mycin.check?? 
b. Blood agarfor freezing: to be frozen for research purposes 
3. Incubate at 37oC and 5% CO2 for 18hrs 
4. On the second day, report antibiotic susceptibility testing results 
5. Freeze optochin sensitive fresh grown colonies of Streptococcus pneumonia according to 
freezing protocol in a screw capped 1.5ml eppendorf tube that is also labeled with the 
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same patient code and also given a serial number on the cap  – fresh grown colonies on 
blood agar 25% glycerol/BHI at -80
o
C.  
6. Enter  the patients data and AST results into the computerized research file 
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Protocol for invasive pneumococcal disease (IPD) 
  in Hospitals 
1. Start from positive blood culture bottles –  Following 24h incubation in 37oC in 5% CO2 
2. Differentiate gram positive from gram negative by culturing the sample on blood agar, 
macconkey agar and on chocolate agar. 
3. Incubate for 18 hrs at 37 oC 
4. In case of alpha hemolysis and colony characteristics typical to Streptococcus pneumoni-
ae then sub-culture as the following: 
a. Plate 1: on Blood agar (to be transported for research) and call the person in 
charge for this project 
b. Plate 2 &3: on blood agar for antibiotic susceptibility testing (AST) for optochin 
(ethylhydrocupreine hydrochloride) sensitivity and other Antibiotics susceptibil-
ity) including penicillin, ceftriaxone, erythromycin and clindamycin should be 
performed following CLSI guidelines. Other suggested antibiotics: tetracycline, 
TMP/SMX, ofloxacin and vancomycin.  
5. label plate 1 of optochin susceptible isolates with a green barcode and label the patient 
data sheet with the same code 
6. Incubate all plates at 37oC for 18hrs and confirm your finding to the project assigned per-
son. 
7. Fill basic data collection of each case - see attached questionnaire 
8. Report if Step. pneumoniae was within 72h of hospitalization or after 72h of hospitaliza-
tion 
9. Into your computer research file, fill in all the required data 
10. Arrange for plate 1 to be transported at 4oC  during 8 hours to the central laboratory in 
Ramallah  
11. In the central laboratory in Ramallah, plates and their data sheets should handed to 
______________ 
12. Call the person in charge of receiving the samples to confirm proper transportation and 
handling  
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Data Form 
ID of patient______________________ 
Date of Birth_______________________    Date of SP isolation____________ 
Source: Blood / CSF / Other____________ 
Address________________________________  City_________ 
Date of Hospitalization_______________________ Date of Discharge__________ 
At discharge:  Alive  / Dead 
Antibiotic Susceptibility: 
 Pen Cef Ery Clin Tet TMP/ 
SMX 
Oflo van 
S         
I         
R         
MIC         
 
Additional data (from Medical file): 
Major Diagnosis:  Pneumonia  /  Meningitis / Bacteremia with no source / sepsis /          Oth-
er__________ 
Comorbidities: 
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 Yes No  Yes No 
Smoker   Immunosuppressed   
Alcohol Abuse   HIV   
Diabetes Mellitus   Hematologic Malignancy   
Ch. Lung Dis   Bone Marrow Transplant   
Congestive Heart Dis.   Past Neurosurg / CSF leak   
Ch. Liver Dis.   Cirrhosis   
IV drug abuse   Ch. Renal Failure   
Malignancy (non-
hematologic) 
  Splenectomy / asplenic   
 
Protocol for Streptococcus pneumonia in the Central Laboratory in Ramallah 
 
1. In the central laboratory, keep the plates at 4oC 
2. Inform the assigned student that Streptococcus pneumonia samples arrived  
3. Samples should be processed directly according to the below protocol and should be kept 
at -80
o
C 
 
 
 
 
 
 
 
